<!DOCTYPE html><html lang="zh-CN"><head><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta charset="utf-8"><meta property="qc:admins" content="10210420621156375"><meta name="renderer" content="webkit"><title>zangyn - 雪球</title><script>var _write = document.write;
var write = function (str) {
  SNB = window.SNB || {};
  if (_write.apply) {
    SNB.docWrite = function (str) {
      _write.apply(document, arguments);
    }
  } else {
    SNB.docWrite = _write;
  }
};

document.write = write;
</script><meta name="keywords" content="zangyn - 雪球"><meta name="description" content="zangyn - 雪球"><!--<link rel="shortcut icon" href="http://xueqiu.com/favicon.ico">--><link rel="icon" type="image/png" href="http://assets.imedao.com/images/favicon.png"><style>html {display:none}</style><script>if (self == top) {
  document.documentElement.style.display = 'block';
} else if (top.location.host !== 'xueqiu.com') {
  top.location = self.location;
}
var WATCH = {};
WATCH.appStart = 1427781279381
WATCH.pageStart = (new Date()).getTime()</script><link rel="stylesheet" href="http://assets.imedao.com/style/bootstrap-84b5ee.css"><style>body{
  padding-top:40px;
}
/* TODO */
.search .dropdown-menu strong{
  height:12px;
  line-height:12px;
}</style><link rel="apple-touch-icon-precomposed" href="http://assets.imedao.com/images/icon-144.png"><script src="http://assets.imedao.com/js/xdomain-0.6.15.js"></script><script>xdomain.slaves({
  'https://xueqiu.com': '/proxy2.html',
  'https://im0.xueqiu.com': '/proxy2.html',
  'https://im1.xueqiu.com': '/proxy2.html',
  'https://im2.xueqiu.com': '/proxy2.html',
  'https://im3.xueqiu.com': '/proxy2.html',
  'https://im4.xueqiu.com': '/proxy2.html',
  'https://im5.xueqiu.com': '/proxy2.html',
  'https://im6.xueqiu.com': '/proxy2.html',
  'https://im7.xueqiu.com': '/proxy2.html',
  'https://im8.xueqiu.com': '/proxy2.html',
  'https://im9.xueqiu.com': '/proxy2.html'
});</script><script src="http://assets.imedao.com/js/SNB.lib.bundle-b11b47.js"></script></head><body id="his-profile" class=" isPC isNotMobile isNotPad"><script>SNB = window.SNB || {};
jQuery.extend(SNB, {
  data: {},
  env: "production",
  Views: {},
  Templates: {},
  Models: {},
  Collections: {},
  domain: {"host":"http://xueqiu.com","base":"http://api.xueqiu.com","photo":"http://photo.xueqiu.com","stock":"http://api.xueqiu.com","static":"http://assets.imedao.com","staticHttps":"https://js.xueqiu.com","upyun":"http://xqimg.b0.upaiyun.com","pdf":"http://doc.xueqiu.com","im":"http://api.xueqiu.com","shared":"/data/source/snowball-fe/shared/","file":"http://xqfile.imedao.com/"},
  currentUser: {"isGuest":true,"enableIM":true},
  jsVersion: {"05.jquery.cookie.js":"68e2a4","08.templates.js":"4aa7bf","SNB.TopicList.js":"870445","SNB.UsersList.js":"34f02b","SNB.atDialog.js":"b5dce3","SNB.base.js":"0e6b16","SNB.base_simple.js":"8d5f63","SNB.bind_verify.js":"118df1","SNB.calendar.js":"c65d9a","SNB.calendarDialog.js":"929cb0","SNB.calendarSubscribe.js":"e6012c","SNB.capitalReturnRateChart.js":"bd11c3","SNB.cardDialog.js":"ab3d1d","SNB.commentView.js":"bbb8d8","SNB.commonFriends.js":"230e08","SNB.companyInfo.js":"86e7f2","SNB.dialog.js":"1ba7c4","SNB.dm.js":"4c9d34","SNB.dmDialog.js":"c96117","SNB.downloadDialog.js":"68595d","SNB.editor.emotion.js":"ccd772","SNB.editor.js":"adb8a9","SNB.eventShare.js":"7b230c","SNB.financeTableDataInfo.js":"63138a","SNB.follower.js":"83577e","SNB.friends.js":"d90729","SNB.g.bar.js":"8d17c0","SNB.guest.js":"a94f90","SNB.guide.js":"28902b","SNB.helpers.js":"d5327e","SNB.his_home.js":"468d25","SNB.holdStockChart.js":"7fb688","SNB.home.js":"da999e","SNB.hotStock.js":"320cd1","SNB.im.contacts.js":"3d5779","SNB.im.dialog.js":"ee29f9","SNB.im.emotions.js":"158b2d","SNB.im.group_applys.js":"5c11f0","SNB.im.group_joined.js":"3f1895","SNB.im.js":"43351a","SNB.im.message.js":"1c9f8a","SNB.im.model.js":"a8324f","SNB.im.net.js":"ec4486","SNB.im.peer_chat.js":"cb13f1","SNB.im.session_item.js":"bbffaa","SNB.im.sessions_list.js":"eb2ad1","SNB.im.setting.js":"ac0ed0","SNB.im.stranger.js":"8ea9a5","SNB.im.utils.js":"6a455e","SNB.imeigu_fund_topic.js":"712871","SNB.imeigu_index.js":"d4f2e9","SNB.index.login.js":"bba5e1","SNB.inner_trade.js":"7d8321","SNB.interest.js":"eeb1f8","SNB.interview.js":"fa9ef6","SNB.kline.js":"b097fb","SNB.lib.bundle.js":"b11b47","SNB.lib.mobile.js":"8eda9f","SNB.modify_email.js":"0cb2c6","SNB.newChart.js":"453bf1","SNB.newChart.mobile.js":"089c9a","SNB.newProfile.js":"50704d","SNB.password.js":"8bf5ac","SNB.pdfDialog.js":"edc173","SNB.performance-year.js":"55e5b8","SNB.performance.js":"b83bda","SNB.performanceChart.js":"0cc6bc","SNB.performanceView.js":"fde3d9","SNB.performance_mobile.js":"2890ea","SNB.personality.js":"3a3a3d","SNB.portfolio.js":"b332e5","SNB.portfolioNew.js":"291c15","SNB.portfolioShareDialog.js":"b581bf","SNB.profile_info.js":"621d95","SNB.recommend.js":"0444f1","SNB.renderTableTrHtml.js":"d9ecf0","SNB.renderUserView.js":"0ea1a6","SNB.reportSpam.js":"418c1f","SNB.repostDialog.js":"7df4cb","SNB.sameFriend.js":"b18a13","SNB.search.js":"11b42e","SNB.search_ipad.js":"62a216","SNB.search_stock_ipad.js":"6910d7","SNB.setting_user.js":"5d7e30","SNB.shareDialog.js":"1dee89","SNB.similarUsers.js":"72068a","SNB.singleStock.js":"2f733b","SNB.status-edit.js":"a9ae8a","SNB.status.js":"1172f0","SNB.status_mobile.js":"7e19fa","SNB.stockActiveUser.js":"396eeb","SNB.stockFollowers.js":"e124c9","SNB.stockList.js":"941ade","SNB.stockList_new.js":"e5b606","SNB.stockNews.js":"311d94","SNB.stockRecommend.js":"352bad","SNB.stockScreener.js":"352de4","SNB.stockStatus.js":"7af8bd","SNB.talks.js":"e19cae","SNB.third_oauth.js":"1b9e2a","SNB.tipsTalk.js":"83e04f","SNB.tipsTopic.js":"624f0b","SNB.today.js":"ff42db","SNB.today.lib.js":"19681e","SNB.today_topic.js":"9f7844","SNB.tooltip.js":"b57764","SNB.topInfluence.js":"89f31e","SNB.trans.js":"ae4d82","SNB.tweetDialog.js":"9eb539","SNB.typeahead.js":"6c0b76","SNB.userRecommend.js":"5dcade","SNB.userRemark.js":"001ff1","SNB.validator.js":"32794c","SNB.weiboUser.js":"81e080","TGJSBridge.js":"4aaeff","WdatePicker.js":"eb9586","ajaxfileupload.js":"59627b","backbone.0.9.10.js":"5d519b","backbone.js":"d013f1","bootstrap.js":"6bd6fa","calendar.js":"9795e3","checkLogin.js":"38a9a1","config.js":"799ccf","d3.v2.min.js":"1ef3b6","fittext.js":"45db6e","flexpaper.js":"56a735","flexpaper_handlers.js":"623c12","fullcalendar.js":"26781c","g.bar.js":"32785d","g.line-min.js":"2db247","g.pie.js":"46e2f1","g.raphael.js":"630b74","hammer.js":"ec2456","hc_exporting.js":"bb5d9e","hc_grid.js":"3b9851","highcharts.js":"122285","highlight.js":"21d2c6","iScroll.js":"834870","im2014.js":"0216be","im_group_apply.js":"930e3b","imeigu_portfolioIframe.js":"8e3134","imgPlugin.js":"1cb5de","imgUpload.js":"0986a1","infinity.min.js":"0c5941","jquery.color.js":"875798","jquery.galleriffic.js":"e6186f","jquery.hammer.js":"e02a44","jquery.history.js":"6f8651","jquery.imgareaselect.js":"a9d059","jquery.js":"d80a03","jquery.lazyload.min.js":"fb3951","jquery.mousewheel.js":"41ebd2","jquery.pjax.js":"7ccac8","jquery.plugin.pullToRefresh.js":"35465b","jquery.rotate.1-1.js":"60d180","jquery.simplePagination.js":"420bda","jquery.tagsinput.js":"0dce2d","jquery.ui.js":"9ee05e","jquery.uploadify.js":"aac61a","jquery.validate.js":"555531","jquery.vticker.js":"5104ed","jquery.watermark.js":"0cc691","login.js":"094d42","moment.js":"b01d4e","morris.min.js":"92098e","mustache.js":"fbf1b1","perfect-scrollbar-0.4.8.with-mousewheel.min.js":"1bd536","raphael.js":"ea1c64","responsive_slides.min.js":"ea733a","sea.js":"1264a2","share-to-xueqiu.js":"ae4237","single.js":"36ac66","slides.jquery.js":"cd66ff","step01.js":"ceaeeb","subscribe.js":"7d760a","underscore.js":"51b489","userSearch.js":"54d13d","xdomain-0.6.15.js":"575cd5","xdomain.js":"c4e376","zepto.js":"6cdcc6","My97DatePicker/WdatePicker.js":"eb9586","My97DatePicker/calendar.js":"9795e3","SNB.lib.bundle/00.sea.js":"24e81c","SNB.lib.bundle/01.JSON.js":"b459a8","SNB.lib.bundle/02.modernizr.js":"f634b5","SNB.lib.bundle/03.jquery.js":"53538f","SNB.lib.bundle/04.jquery.ui.js":"96c17c","SNB.lib.bundle/05.jquery.cookie.js":"68e2a4","SNB.lib.bundle/06.underscore.js":"d97ed3","SNB.lib.bundle/07.backbone.js":"8a9a44","SNB.lib.bundle/08.templates.js":"4aa7bf","SNB.lib.bundle/10.jade.runtime.js":"1fc7ae","SNB.lib.mobile/1.zepto.min.js":"acaeac","SNB.lib.mobile/2.underscore.js":"c2da07","SNB.lib.mobile/iscroll.js":"4a55be","bootstrap/bootstrap-alert.js":"a9f081","bootstrap/bootstrap-button.js":"ce03ae","bootstrap/bootstrap-carousel.js":"62b76a","bootstrap/bootstrap-collapse.js":"9be616","bootstrap/bootstrap-dropdown.js":"af96b6","bootstrap/bootstrap-modal.js":"cf302e","bootstrap/bootstrap-popover.js":"a4e6a7","bootstrap/bootstrap-scrollspy.js":"a88d39","bootstrap/bootstrap-tab.js":"8f2b45","bootstrap/bootstrap-tooltip.js":"682437","bootstrap/bootstrap-transition.js":"17fa23","bootstrap/bootstrap-typeahead.js":"97f107","common/SNB.helpers.js":"2bdc5e","common/backbone_1.1.2.js":"8531c9","common/css3-mediaqueries.js":"f83d37","common/fastclick.js":"753522","common/jquery-1.9.1.js":"b8b878","common/json.js":"b459a8","common/lib.js":"de2f7c","common/sea-2.3.0.js":"c823d9","common/sea.js":"24e81c","common/underscore_1.6.0.js":"3ffba8","common/util.js":"183faf","common/zepto-core-fx.1.1.3.js":"27e274","common/zepto-deferred.js":"977158","cube/cube_detail.js":"b26446","cube/cube_detail_m.js":"1ea5eb","cube/cube_discover.js":"b16cdd","cube/cube_discover_m.js":"b9ea8b","cube/cube_edit.js":"d058ee","cube/cube_guide.js":"88a7d5","cube/cube_recommend.js":"eb4aa8","cube/post_grid.js":"730811","cube/profile_cubes.js":"593e28","cube/range_slider.js":"358302","cube/stock_edit_modal.js":"9ad913","highcharts/jquery-1.6.4.min.js":"526f75","im2014/base.adapter.deliver.js":"17ba5b","im2014/base.adapter.js":"e895d8","im2014/base.config.js":"710ff1","im2014/base.js":"58869d","im2014/base.localstorage.js":"57720d","im2014/base.net.js":"540257","im2014/base.utils.js":"8cb3f7","im2014/db.contacts.js":"536985","im2014/db.groups.js":"aebe8f","im2014/db.js":"b1164d","im2014/db.message.helper.js":"0fa7e8","im2014/db.messages.js":"cd2db6","im2014/db.sessions.js":"b428e2","im2014/im.js":"3675e3","im2014/session.dialog.js":"34f336","im2014/session.editor.js":"fc99c9","im2014/session.gmm.js":"44c0a0","im2014/session.item.js":"2f722e","im2014/session.joingroup.js":"34f898","im2014/session.list.js":"35a7ff","im2014/session.message.js":"30b56c","im2014/session.setting.js":"a5fdcb","im2014/widget.emotion.js":"e07cbb","im2014/widget.joingroup.js":"b2ee4c","im2014/widget.requestjoingroup.js":"319aaa","im2014/widget.search.js":"2d2eda","im2014/widget.uploader.js":"e1abec","im2014/widget.viewer.js":"93c152","imeigu/xueqiu_popup.js":"61979d","lang/en.js":"c6550c","lang/zh-cn.js":"a606a6","lang/zh-tw.js":"4e0fdb","lib/autoresize.js":"f853a5","lib/chai.js":"a0130d","lib/jquery.easing.1.3.js":"008f85","lib/jquery.fullPage.js":"f69025","lib/mocha.js":"8799cd","lib/store.js":"9c7667","lib/ueditor.js":"2e0f51","lib/upload.js":"8837c4","pages/home.js":"1112bf","pages/single.js":"0a3e7d","widget/TSNB.addfriend.js":"f04fd7","widget/TSNB.addpdf.js":"d185b8","widget/TSNB.addstock.js":"0c459a","widget/TSNB.at.js":"a5ebeb","widget/TSNB.bindverify.js":"f3ea69","widget/TSNB.home-editor.js":"123ca2","widget/TSNB.newuser-guide.js":"3bc710","widget/TSNB.people-autocomplete.js":"92ed61","widget/TSNB.performance.js":"27b5e6","widget/TSNB.sharestatus.js":"16e249","widget/TSNB.stockalert.js":"1cb0fd","widget/TSNB.stockgroup.js":"7baec6","widget/TSNB.typeahead.js":"6e6634","widget/aside.js":"46008f","widget/backbone1.1.2.js":"181b4a","widget/bootstrap.js":"abac2a","widget/donate.js":"312591","widget/donate_tooltip.js":"435b5f","widget/editor.js":"25fcd3","widget/emotions.js":"623bc3","widget/favorite.js":"e356ee","widget/forward.js":"fb609b","widget/global_pin.js":"4c1878","widget/lodash.underscore.js":"1854ff","widget/profile_pin.js":"fb4311","widget/report_spam.js":"2e5e63","widget/repost_comment.js":"4bb3ae","widget/share.js":"6e71c0","widget/status.js":"d06d1e","widget/underscore1.6.0.js":"4d7fd6","widget/util.js":"c0629c","My97DatePicker/lang/en.js":"c6550c","My97DatePicker/lang/zh-cn.js":"a606a6","My97DatePicker/lang/zh-tw.js":"4e0fdb","bootstrap/tests/phantom.js":"e38dfa","bootstrap/tests/server.js":"21e92a","common/lib/jquery-1.9.1.js":"3dd6ee","common/lib/sea-2.3.0.js":"c823d9","common/lib/underscore_1.6.0.js":"834fa8","common/util/image.js":"73664d","common/util/jade.runtime.js":"aed6b5","common/util/jquery.extend.js":"cb4243","common/util/observer.js":"648151","common/util/password.js":"ef4528","common/util/upload.js":"8f1294","pages/about/app.js":"eecbff","pages/about/app_mobile.js":"7db607","pages/broker/TSNB.bind.js":"e8ed5d","pages/consultant/consultant-market.js":"2bc801","pages/event/TSNB.year-summary-mobile.js":"73f230","pages/event/TSNB.year-summary.js":"daff60","pages/event/cmc.js":"a7c273","pages/home/timeline.js":"1112bf","pages/invest/SNB.chart_base.js":"285f6f","pages/invest/SNB.fund_chart.js":"4a2cb1","pages/invest/SNB.mobile_chart.js":"bc032b","pages/invest/SNB.mobile_stock.js":"d942d7","pages/invest/SNB.profile_broker_rank.js":"85311d","pages/invest/SNB.rank.js":"677dd5","pages/invest/chart.js":"02e6ce","pages/pay/deposit-mobile.js":"799d95","pages/pay/deposit.js":"e37ac4","pages/pay/donate-mobile.js":"153feb","pages/pay/pin.js":"1804ea","pages/pay/subscribe-mobile.js":"c6187b","pages/pay/withdraw.js":"952521","pages/sns/index.js":"a6c885","pages/sns/single.js":"120bdc","pages/today/mobile.index.js":"f72378","pages/user/login.js":"ff5499","widget/aside/TSNB.ad.js":"55466e","widget/aside/TSNB.hot-stocks.js":"44327c","widget/aside/TSNB.interesting-people.js":"b01b82","widget/aside/TSNB.other-services.js":"70e391","widget/aside/TSNB.recommend-people.js":"7ddb30","widget/aside/TSNB.sysnotify.js":"e50d01","widget/aside/TSNB.today-talk.js":"8fa37c","widget/bootstrap/affix.js":"f014e8","widget/bootstrap/alert.js":"915f20","widget/bootstrap/bootstrap-datepicker.js":"daa8d6","widget/bootstrap/button.js":"3a8a2e","widget/bootstrap/carousel.js":"f763e0","widget/bootstrap/collapse.js":"c9ceab","widget/bootstrap/dropdown.js":"164604","widget/bootstrap/modal.js":"d390dd","widget/bootstrap/popover.js":"8c9993","widget/bootstrap/scrollspy.js":"37bd38","widget/bootstrap/tab.js":"5df6c4","widget/bootstrap/tooltip.js":"b973d7","widget/bootstrap/transition.js":"7af948","widget/bootstrap/typeahead.js":"1e1e67","widget/editor/at.js":"41b184","widget/editor/emotion.js":"bd52eb","widget/editor/umeditor.config.js":"ed3336","widget/editor/umeditor.js":"6b7121","widget/editor/zh-cn.js":"16b3e4","widget/flexpaper/flexpaper.js":"56a735","widget/flexpaper/flexpaper_handlers.js":"39b20d","widget/mobile/action.js":"43495d","widget/mobile/form.js":"03c77e","widget/mobile/modal.js":"309f6a","widget/mobile/overlay.js":"44e1eb","widget/status/comment.js":"239e91","widget/status/data.js":"d2678b","widget/status/pdf.js":"0af8cc","widget/status/pin.js":"4dce9c","widget/tmp/SNB.base.js":"73a62a","widget/tmp/json.js":"b459a8","widget/util/TSNB.donate.js":"dabf92","widget/util/areas.js":"4f6252","widget/util/modal.js":"0a947f","widget/util/notice.js":"c2c3a1","widget/util/share.js":"8c017a","widget/util/tooltip.js":"30a8e8","widget/util/typeahead.js":"f70471","widget/util/user.js":"9b9c3a","bootstrap/tests/unit/bootstrap-alert.js":"93d6ac","bootstrap/tests/unit/bootstrap-button.js":"996b53","bootstrap/tests/unit/bootstrap-carousel.js":"54a2cf","bootstrap/tests/unit/bootstrap-collapse.js":"1b1262","bootstrap/tests/unit/bootstrap-dropdown.js":"6a491c","bootstrap/tests/unit/bootstrap-modal.js":"6dd5a0","bootstrap/tests/unit/bootstrap-phantom.js":"940ffb","bootstrap/tests/unit/bootstrap-popover.js":"4f65eb","bootstrap/tests/unit/bootstrap-scrollspy.js":"bd7b2c","bootstrap/tests/unit/bootstrap-tab.js":"63f9fc","bootstrap/tests/unit/bootstrap-tooltip.js":"fc2c1c","bootstrap/tests/unit/bootstrap-transition.js":"a1b2cc","bootstrap/tests/unit/bootstrap-typeahead.js":"2f86e0","bootstrap/tests/vendor/jquery.js":"fcf997","bootstrap/tests/vendor/qunit.js":"a8c0db","pages/invest/chart/TSNB.chart.base.js":"33cd3a","pages/invest/chart/TSNB.chart.compare.js":"6b4c52","pages/invest/chart/TSNB.chart.event.js":"23af89","pages/invest/chart/TSNB.chart.kline.js":"3a1e79","pages/invest/chart/TSNB.chart.status.js":"62d5f1","pages/invest/chart/TSNB.chart.stock.js":"770897","pages/invest/chart/TSNB.chart.thumbnail.js":"52101d","pages/invest/hq/TSNB.compare_ah.js":"8dcaea","pages/invest/portfolio/TSNB.create-portfolio-group.js":"d9e67b","pages/invest/portfolio/TSNB.delete-portfolio-group.js":"af94fb","pages/invest/portfolio/TSNB.delete-portfolio.js":"1a6838","pages/invest/portfolio/TSNB.manage-portfolio-group.js":"1b0504","pages/invest/portfolio/TSNB.portfolio-util.js":"d78b8f","pages/invest/portfolio/TSNB.portfolio.js":"6580b6","pages/invest/portfolio/TSNB.stock-autocomplete.js":"cc5d2e","pages/sns/index/cube.js":"1f5d94","pages/sns/index/login.js":"665dd7","pages/sns/index/markets.js":"b51353","pages/sns/index/promotion.js":"aa01d3","pages/sns/index/stocks.js":"47fe9b"},
  cssVersion: {"about.css":"8a68c7","activate_bar.css":"90db89","bootstrap-lite.css":"09c973","bootstrap.css":"84b5ee","bootstrap_full.css":"66069a","bootstrap_tab_xueqiu.css":"69dee9","bootstrap_tab_xueqiu_white.css":"5492e5","button.css":"23513c","chart.css":"d41d8c","comment.css":"dbfbd5","connect_link.css":"0edf0b","default.css":"165b51","default_mobile.css":"264592","dh.css":"a34780","dialog.css":"828547","editor.css":"57d8ef","editor_inline.css":"7d7563","flexpaper.css":"ecc108","form.css":"c845bd","fullcalendar.css":"b1f726","guide_overlay.css":"9dd1cf","hots-statuses.css":"181d4e","icon.css":"680a07","im.css":"aa2f71","im2014.css":"dbd489","imgroup.css":"5445f8","jinNang.css":"4bd30a","jinnang_1394597838763.css":"4bd30a","jquery.tagsinput.css":"3f47e0","jquery.ui.css":"279647","mentions_block.css":"4b58aa","mocha.css":"a5dea9","mystatus.css":"272433","newChart.css":"5d9be9","pdfviewer.css":"720dd9","performance-year-mobile.css":"a17f1a","performance-year.css":"317994","performanceChart.css":"2589d4","personality-ie8.css":"6a37b0","personality.css":"c723c4","pop_login.css":"8f20df","portfolioIframe.css":"c85adf","portfolioNew.css":"4f2887","profile.css":"0737fc","profile_info.css":"4b5978","profile_operations.css":"a0abbd","profile_status.css":"01d683","pull-to-refresh.css":"3e5b69","searchBar.css":"aeef28","simplePagination.css":"b23401","snowbrick.css":"ccc31a","status_mobile.css":"4c93b3","status_operate_btn.css":"0872af","tab-setting.css":"506d45","today_topic.css":"a8f864","tooltip.css":"820355","uploadify.css":"d5b49f","userRecommend.css":"beabbe","user_list.css":"bb06fd","widget.css":"88e99b","widget_user.css":"d1e0c0","common/base.css":"2262f2","common/grid.css":"ad0354","common/iconfont.css":"5cf08f","common/layout.css":"746a95","common/menu.css":"985468","common/mobile.css":"3362b1","common/mod.css":"e27423","common/modal.css":"f9111d","common/nav-bar.css":"c37184","common/pager.css":"0d5b09","common/reset.css":"e2dffc","common/var.css":"d41d8c","cube/cube_card.css":"ae3e1a","cube/cube_detail.css":"d97083","cube/cube_detail_m.css":"9ac92d","cube/cube_discover.css":"30d439","cube/cube_discover_m.css":"d02a1d","cube/cube_edit.css":"f5208f","lib/jquery.fullPage.css":"3dfa38","pages/TSNB.about.css":"28449a","pages/home.css":"3ef6f1","pages/imeigu.css":"d51b5b","pages/post.css":"16fd7a","pages/profile.css":"093e27","pages/status.css":"cc43c8","pages/tip.css":"9bc5a0","touch/common.css":"1c57df","touch/normal.css":"d536b7","widget/TSNB.comment.css":"705fe6","widget/TSNB.donate.css":"708f8a","widget/TSNB.donate_tooltip.css":"672acf","widget/TSNB.performance.css":"588cce","widget/TSNB.portfolio_dialog.css":"68b2cb","widget/TSNB.portfolio_user_dialog.css":"9ad4f2","widget/TSNB.report_spam.css":"3e795c","widget/TSNB.share.css":"f36d77","widget/TSNB.status.css":"024cfd","widget/TSNB.user_dialog.css":"81075a","widget/btn.css":"9fdda0","widget/datepicker.css":"d683e7","widget/donate.css":"ab255d","widget/donate_tooltip.css":"9e0336","widget/global_pin.css":"92b1cf","widget/modal.css":"5fc4e9","widget/profile_pin.css":"60296d","common/css3/inline-block.css":"bb8c38","pages/about/animation.css":"1e4355","pages/about/app.css":"d919d8","pages/about/app_mobile.css":"5b4c12","pages/about/share.css":"6712c8","pages/consultant/consultant.css":"138686","pages/event/TSNB.year-summary-mobile.css":"864fa2","pages/event/TSNB.year-summary.css":"a868f5","pages/event/cmc-mobile.css":"7fe9f7","pages/event/cmc.css":"8d1acc","pages/home/home-editor.css":"a4a479","pages/home/newuser-guide.css":"23dd61","pages/home/widgets.css":"cfae61","pages/index/cube.css":"cc49b2","pages/index/default.css":"417e7b","pages/invest/dealList.css":"79d551","pages/invest/mobile_chart.css":"31d833","pages/invest/mobile_performance.css":"16e7bb","pages/invest/mobile_stock.css":"4a4c6d","pages/invest/profile_broker_rank.css":"55a18e","pages/invest/rank.css":"4d6196","pages/invest/stock_chart.css":"0eeda7","pages/mobile/common.css":"004801","pages/mobile/vars.css":"d41d8c","pages/pay/subscribe-mobile.css":"128827","pages/pay/wallet-mobile.css":"583bc0","pages/pay/wallet.css":"f7af19","pages/pin/pin-mobile.css":"bf2ba8","pages/sns/TSNB.single.css":"775597","pages/sns/home.css":"8f62db","pages/today/index-mobile.css":"a95cc9","pages/user/login.css":"ba73c8","widget/bootstrap/alerts.css":"2c520b","widget/bootstrap/badges.css":"da050d","widget/bootstrap/bootstrap.css":"971848","widget/bootstrap/breadcrumbs.css":"b9ab35","widget/bootstrap/button-groups.css":"a7c65b","widget/bootstrap/buttons.css":"a73cc0","widget/bootstrap/carousel.css":"93e128","widget/bootstrap/close.css":"30812b","widget/bootstrap/code.css":"fab06a","widget/bootstrap/component-animations.css":"63295e","widget/bootstrap/dropdowns.css":"d91661","widget/bootstrap/forms.css":"1dac09","widget/bootstrap/glyphicons.css":"024db0","widget/bootstrap/grid.css":"7f9bd0","widget/bootstrap/input-groups.css":"fc56c7","widget/bootstrap/jumbotron.css":"cf17ad","widget/bootstrap/labels.css":"3e0971","widget/bootstrap/list-group.css":"ec9751","widget/bootstrap/media.css":"ecbd91","widget/bootstrap/mixins.css":"a0cb66","widget/bootstrap/modals.css":"5b2682","widget/bootstrap/navbar.css":"abacbf","widget/bootstrap/navs.css":"9fbe5c","widget/bootstrap/normalize.css":"ddcb0b","widget/bootstrap/pager.css":"7be0a4","widget/bootstrap/pagination.css":"eaa566","widget/bootstrap/panels.css":"d53a2d","widget/bootstrap/popovers.css":"93bafa","widget/bootstrap/print.css":"b11602","widget/bootstrap/progress-bars.css":"580cf9","widget/bootstrap/responsive-embed.css":"1c5626","widget/bootstrap/responsive-utilities.css":"2db01f","widget/bootstrap/scaffolding.css":"0fc3a2","widget/bootstrap/tables.css":"462165","widget/bootstrap/theme.css":"52929d","widget/bootstrap/thumbnails.css":"b96eb4","widget/bootstrap/tooltip.css":"c060af","widget/bootstrap/type.css":"c8dff8","widget/bootstrap/utilities.css":"d3b1aa","widget/bootstrap/variables.css":"d41d8c","widget/bootstrap/wells.css":"578e1c","widget/mobile/modal.css":"f2f776","widget/mobile/normal.css":"d536b7","widget/mobile/top-bar.css":"f4eb52","widget/umeditor/editor.css":"5f1892","widget/umeditor/umeditor.css":"7eb569","widget/util/page.css":"3ea87c","pages/home/widgets/ad.css":"4f1e5e","pages/home/widgets/hot-stocks.css":"9c722b","pages/home/widgets/interesting-recommend.css":"25f080","pages/home/widgets/my-nav.css":"c4c64e","pages/home/widgets/other-services.css":"d76f0d","pages/home/widgets/sysnotify.css":"116c48","pages/invest/portfolio/group.css":"3e96d2","pages/invest/portfolio/portfolio.css":"f2f39b","widget/bootstrap/mixins/alerts.css":"d41d8c","widget/bootstrap/mixins/background-variant.css":"d41d8c","widget/bootstrap/mixins/border-radius.css":"d41d8c","widget/bootstrap/mixins/buttons.css":"d41d8c","widget/bootstrap/mixins/center-block.css":"d41d8c","widget/bootstrap/mixins/clearfix.css":"d41d8c","widget/bootstrap/mixins/forms.css":"d41d8c","widget/bootstrap/mixins/gradients.css":"d41d8c","widget/bootstrap/mixins/grid-framework.css":"d41d8c","widget/bootstrap/mixins/grid.css":"2f25b9","widget/bootstrap/mixins/hide-text.css":"d41d8c","widget/bootstrap/mixins/image.css":"d41d8c","widget/bootstrap/mixins/labels.css":"d41d8c","widget/bootstrap/mixins/list-group.css":"d41d8c","widget/bootstrap/mixins/nav-divider.css":"d41d8c","widget/bootstrap/mixins/nav-vertical-align.css":"d41d8c","widget/bootstrap/mixins/opacity.css":"d41d8c","widget/bootstrap/mixins/pagination.css":"d41d8c","widget/bootstrap/mixins/panels.css":"d41d8c","widget/bootstrap/mixins/progress-bar.css":"d41d8c","widget/bootstrap/mixins/reset-filter.css":"d41d8c","widget/bootstrap/mixins/resize.css":"d41d8c","widget/bootstrap/mixins/responsive-visibility.css":"d41d8c","widget/bootstrap/mixins/size.css":"d41d8c","widget/bootstrap/mixins/tab-focus.css":"d41d8c","widget/bootstrap/mixins/table-row.css":"d41d8c","widget/bootstrap/mixins/text-emphasis.css":"d41d8c","widget/bootstrap/mixins/text-overflow.css":"d41d8c","widget/bootstrap/mixins/vendor-prefixes.css":"d41d8c"},
  staticDomain: 'http://assets.imedao.com',
  bid : ''
});

SNB.data.access_token =  $.cookie("xq_a_token") || "7fd433866f17942022661a942c06f2b5fe387c88";
</script><!-- 防止局域网缓存用户信息--><script>(function(){
  var search = window.location.search || '';
  if (search.indexOf('_=') === -1 && SNB.bid !== '' && document.cookie && document.cookie.indexOf('bid=' + SNB.bid) === -1) {
    var searchArr = search.split('&');
    searchArr.push('_=' + (+new Date).toString(36));
    window.location.search = search.join('&');
  }
})();
</script><script src="http://assets.imedao.com/js/05.jquery.cookie.js"></script><script>function delCookie(name){//为了删除指定名称的cookie，可以将其过期时间设定为一个过去的时间
  var date = new Date();
  date.setTime(date.getTime() - 10000);
  document.cookie = name + '=a; expires=' + date.toGMTString();
}
/*
if(!$.cookie('xq_refresh') && $.cookie('xq_a_token')){
  $.ajax({
    url: '/user/refreshCookie',
    async: false
  }).done(function(){
    delCookie('xq_a_token');
    delCookie('xq_r_token');
    delCookie('xq_token_expire');
  });
}
*/
jQuery(function($){
  $('.navbar a.exit').on('click', function(){
    try{
      delCookie('xq_a_token');
      delCookie('xq_r_token');
      delCookie('xq_token_expire');
    } catch(e){
      console.log(e);
    }
  });
});</script><script src="http://assets.imedao.com/js/SNB.helpers-d5327e.js"></script><script>SNB.profileUser = {"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":130,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png!50x50.png","profile_image_url_small":"community/default/avatar.png!30x30.png"}</script><noscript><style>html {
  display: block
}</style><p class="ie6">当前浏览器禁用了JavaScript，导致不能正常使用雪球的功能，请打开JavaScript后再访问本站。</p></noscript><!--[if lt IE 8]><div class="ie6">你正在使用的浏览器版本过低（IE7或IE7以下，包括套用了IE内核的360浏览器、搜狗浏览器等）。<br />如果不能正常浏览本站或某些功能无法使用，请到微软官网下载升级 <a href="http://windows.microsoft.com/zh-CN/internet-explorer/downloads/ie">Internet Explorer</a> 或使用 <a href="http://www.google.com/chrome/">谷歌 Google Chrome</a> 浏览器。</div><![endif]--><div class="temp"></div><div class="navbar navbar-fixed-top"><div class="navbar-inner"><div class="container"><h1 id="logo"><a href="/"><img title="返回我的首页" src="http://assets.imedao.com/images/logo@2x.png" width="54px" height="30px" alt="雪球"></a></h1><div class="search"><form method="get" action="/k"><input id="quick-search" name="q" type="text" autocomplete="off" placeholder="搜索 股票/讨论/用户/群组" class="typeahead"></form><span class="icon"><i></i></span></div><ul class="nav pull-right account notlogined"><li><a href="/account/reg" class="reg">注册</a></li><li><a href="/" class="login">登录</a></li></ul></div></div></div><!--!=css('im.css')--><script>seajs.config({
  timeout: 60000,
  preload: [SNB.jsVersion && _.keys(SNB.jsVersion).length ? 'SNB.base-' + SNB.jsVersion['SNB.base.js'] + '.js' : 'SNB.base.js']
})
</script><script>seajs.use("SNB.guest.js")
</script><script>;(function () {
  var keys = _.keys(SNB.jsVersion)
    , map = [];
    
  if (keys.length) {
    _.each(keys, function(k) {
      var reg = new RegExp('\\/(' + k.replace(/\./g, '\\.') + ')(\\?.*|$)');
      
      map.push([reg, function (all, fileName, param) {
        var result = '/' + fileName.replace(/\.js$/i, '') + '-' + SNB.jsVersion[k] + '.js';
        
        if (param) {
          result += param;
        }
        
        return result;
      }]);
    });
    
    seajs.config({
      map: map
    });
  }
}())
</script><!-- test config--><script src="http://assets.imedao.com/js/bootstrap-6bd6fa.js"></script><div id="center" class="container"><div class="main"><div style="display:none" class="loading"></div><div class="wrapper"><link rel="stylesheet" href="http://assets.imedao.com/style/pages/profile-093e27.css"><div class="profile_box container "><div class="profile_box_behaviour"><div class="profile_box_operations"><div class="profile_operations"><ul class="operations relation"><li class="relationship"><span class="op addFriendBtn"><b>＋</b>加关注</span></li><li><a href="javascript:;" data-toggle="at" data-target="zangyn" class="at">@他</a></li><li><a href="javascript:;" class="block">拉黑</a></li><li><a href="javascript:;" class="reportSpam_user">举报</a></li></ul></div></div><div class="profile_box_users"><div style="display:none" class="usersList similarUser_list head-list"></div><script>seajs.use('SNB.similarUsers.js', function(){
  var collection=new SNB.Collections.similarUsers();
  collection.fetch({
    success:function(){
      var col_length = collection.length;
      if(col_length){
        var views=new SNB.Views.similarUsersList({el:$(".similarUser_list"),collection:collection});
        views.render();
        $(".similarUser_list").prepend("<h3>兴趣相近</h3>").show();
      }
    }
  })
})</script></div></div><div class="profile_box_info"><div class="profile_info"><div class="profile_info_pic"><img src="http://xavatar.imedao.com/community/201210/1352439404964-20121221.png!100x100.png" width="100" height="100"/></div><div class="profile_info_content"><h2><span>zangyn</span><a href="＃" style="display:none" data-user-id='6785033954' data-user-name="zangyn" class="setRemark">(备注)</a></h2><script>seajs.use("SNB.base.js", function(){
  SNB.get("/user/profile/show.json", {uid: SNB.profileUser.id, property: "card_sid,personality"}, function(data) {
    $(".profile_info_content h2").append("<a target='_blank' title='雪球名片' style='margin-left:6px' href='" + SNB.profileUser.profile + "/card'><img title='雪球名片' src='http://assets.imedao.com/images/card/" + (data[0]?'namecard-icon2.png':'namecard-icon2-gray.png') + "'/></a>")
    var p = data[1] && data[1].value != 'false';
    $(".profile_info_content h2").append("<a target='_blank' title='投资者性格" + (p ? '：' + SNB.Util.personalityResult(data[1].value) : '') + "' style='margin-left:6px' href='/event/personality/x/" + (SNB.profileUser.domain || SNB.profileUser.id) + "'><img title='投资者性格" + (p ? '：' + SNB.Util.personalityResult(data[1].value) : '') + "' src='http://assets.imedao.com/images/personality/icon_character" + (p ? '' : '_gray') + ".png'/></a>")
  })
})</script><ul><li class="gender_info"><span class="m head"></span>男&nbsp;&nbsp;&nbsp;海外澳大利亚&nbsp;&nbsp;&nbsp;</li><li>股票130只&nbsp;&nbsp;讨论7506条&nbsp;&nbsp;粉丝200893人</li><li><div class="item_title">能力圈：</div><div class="item_content discuss_stock_list"><span title="科大讯飞" class="discuss_stock">科大讯飞，</span><span title="中国平安" class="discuss_stock">中国平安，</span><span title="中信证券" class="discuss_stock">中信证券</span></div></li><li><div class="item_title">简介：</div><div class="item_content expend_in_oneline"><p class="summary">如果不上雪球，你就输在了投资的起跑线上。</p><p style="display:none" class="detail">如果不上雪球，你就输在了投资的起跑线上。<span class="fold_all">收起<i class="newIcon_expend"></i></span></p></div></li></ul></div></div><script>seajs.use("SNB.base.js", function(){
  SNB.get("/account/oauth/user/show.json",{source:"sina",userid:SNB.profileUser.id},function(ret){
    if(ret && ret.id){
      $(".profile_info").find("ul li").eq(0).append("<a href='http://weibo.com/"+ret.id+"' target='_blank'><span class='newIcon newIcon_weibo'>&nbsp;</span> 微博</a>")
    }
  })
  $(".show_all,.fold_all").on("click",function(e){
    e.preventDefault();
    var that = this;
    $(that).closest(".expend_in_oneline").find("p").toggle();
  })
})</script></div></div><link rel="stylesheet" href="http://assets.imedao.com/style/pages/invest/profile_broker_rank-55a18e.css"><div class="rank-container"><div class="rank-groups newtab"><ul class="nav nav-tabs rank-tabs"></ul><span class="desc">每天的数据将于第二个交易日13:00前更新，由用户及<a href="http://bj.cgws.com/Default.jsp" target="_blank">长城证券</a>授权提供。</span><a href="http://xueqiu.com/3945550771/31966036" class="link">榜单说明</a><a href="http://xueqiu.com/event/rank/gws" class="link">看看其他人</a></div><div class="rank-wrapper"><div class="rank-performance"><div class="performance-title"><span class="title">账户收益</span></div><div class="performance-chart"><div class="performance-info"><div class="performance-income"><div id="pchart"></div><div class="performance-rate"><p class="desc">参赛后的收益率</p><p class="income"> </p><p class="time">参赛时间：-</p><div class="rank-stocks"><p><span class="title">持股前五：</span></p></div></div></div><div class="rank-hold"><div class="rank-day-rate"><p class="data">-</p><p class="desc">日收益</p></div><div class="rank-assets"><p class="data">-</p><p class="desc">净资产</p></div><div class="rank-marketValue"><p class="data">-</p><p class="desc">总市值</p></div><div class="rank-rate"><p class="data">-</p><p class="desc">持仓比例</p></div></div></div></div></div><div class="rank-chart"><div id="capitalReturnRateChartContainer" class="chartContainer"><div class="noData"><span>请您在券商处同步盈亏，或券商暂未支持同步。 </span></div><div class="head"><h3> <a href="/performance">收益率</a></h3><span class="timeInterval"></span><span class="dropdown"><span>业绩对比</span><span class="caret"></span></span></div><div id="ROAStateInfo" class="stateInfo"><span class="stockInfo"><span class="sign"></span><span class="stockName">盈亏 </span><span class="stockUp"></span></span><div class="loadState">数据载入中    </div></div><div id="capitalReturnRateChart"></div><div class="chartInfo"><ul class="selectTime"><li id="1m" class="selected">1月</li><li id="3m">3月</li><li id="6m">6月</li><li id="1y">1年</li><li id="3y">3年</li><li id="5y">5年</li><li id="all">全部</li></ul><span class="info">仅自己可见</span></div><div id="popCompare"><div class="popLeft"><label class="checkbox"> <input type="checkbox" symbol="SH000001"/>上证指数</label><label class="checkbox"> <input type="checkbox" symbol="SZ399001"/>深证指数</label><label class="checkbox"> <input type="checkbox" symbol="HKHSI"/>恒生指数</label><label class="checkbox"> <input type="checkbox" symbol="SP500"/>标准普尔500指数</label><label class="checkbox"> <input type="checkbox" symbol="NASDAQ"/>纳斯达克指数</label><label class="checkbox"> <input type="checkbox" symbol="DJI30"/>道琼斯指数</label><label class="checkbox"> <input type="checkbox" symbol="ICS30"/>i美股中概30指数</label><label class="checkbox"> <input type="checkbox" symbol=""/><input id="searchCompareStock" type="input" placeholder="股票名称/代码"/></label></div><div class="popRight"></div><div class="popClose"><button class="btn">关闭</button></div></div></div><div class="rank-industry"><div class="industry-title">行业分布</div><div class="industry-chart"></div></div></div><div class="rank-tran">   <div class="tran-title"><span class="title">交易历史</span><a href="#" class="show-trans">交易<span class="tran-num"></span>笔，点击查看</a></div><div class="tran-list"></div><div class="hide-tran-list"><a href="#">收起</a></div></div><div class="rank-status"><div class="status-title"><span class="title">关于"百度(BIDU)的讨论"</span><a href="#" class="back-trans">返回交易历史</a></div><div class="tran-status-list"></div></div></div></div><script src="http://assets.imedao.com/js/pages/invest/SNB.profile_broker_rank-85311d.js"></script><style>.cube-follow {
  text-decoration: none;
  cursor: pointer;
}

.cube-follow span {
  display: none;
  width: 20px;
  height: 12px;
  margin:0 3px;
}

.cube-follow-false .add {
  display: inline-block;
  background: url(http://assets.imedao.com/images/profile_cube_image.png) no-repeat -18px -1px;
}

.cube-follow-true .del {
  display: inline-block;
  background: url(http://assets.imedao.com/images/profile_cube_image.png) no-repeat  0px -1px;
}

a.rebalance {

  display: inline-block;
  background: url(http://assets.imedao.com/images/profile_cube_image.png) no-repeat -60px 0px;
  width: 20px;
  height: 12px;
}
a.contact{
  background: url(http://assets.imedao.com/images/profile_cube_image.png) no-repeat -40px 0px;
  display: inline-block;
  width: 20px;
  height: 12px;
}
.limit{
  background: none!important;
  width: auto!important;
  margin: 0!important;
  
}
.moreC{
  background: none;
  border: none;
  color: #0055A2;
  cursor: pointer;
  height: 20px;
  line-height: 20px;
  margin: 0;
  padding: 5px 6px 5px 15px;
  text-align: right;
  border-top: 1px solid #DDD;
}
.none{
  padding: 15px;
  font-size: 14px;
  text-align: center;
  color: #aaa;
}

</style><div class="profile-cube-list portfolioContainer"><div class="cube-title newtab"><ul style="float:left;display:block" class="nav nav-tabs"><li class="active"><a class="nav nav-tabs">他创建的组合(<i class="num">--</i>)</a></li></ul><div class="clear"></div></div><div class="tableContainer"><table><thead><tr><th>组合</th><th>最新净值</th><th>总收益</th><th width="87px">操作</th></tr></thead><tbody><tr><td colspan="4"><div class="loading"></div></td></tr></tbody></table></div></div><script>$.ajax({
  url:"/cubes/count_limit.json",
  data:{
    user_id:SNB.profileUser.id
  },
  type:"get"
}).success(function(data){
  $('.profile-cube-list .cube-title .num').text(data.exists_count);
  $('.profile-cube-list .cube-title .limit').text(data.allow_count);
  
})
seajs.use('cube/profile_cubes.js');
</script><div class="portfolioContainer"><div class="newtab"><ul id="portfolioTab" class="nav nav-tabs"></ul><div class="clear"></div></div><div class="tableContainer"><table class="portfolioNew"><thead><tr><th style="min-width:120px;">股票</th><th style="min-width:40px;">当前价 </th><th style="min-width:80px;">买入目标价</th><th style="min-width:80px;">卖出目标价</th><th>备注</th></tr></thead><tbody><tr><td colspan="7"><div class="loading"></div></td></tr></tbody></table></div></div><script src="http://assets.imedao.com/js/jquery.mousewheel-41ebd2.js"></script><script src="http://assets.imedao.com/js/raphael-ea1c64.js"></script><script>seajs.use('SNB.dialog.js')
seajs.use(['SNB.newChart.js', 'SNB.portfolioNew.js'],function(_c, p){
  var portfolio=new p.Portfolio();
})</script><div class="status_box "><div class="statuses_tab newtab"><ul class="nav nav-tabs"><li id="statusMenu" class="dropdown active status_tab"><a href="#status_content" data-target="#statusMenu" data-type="" data-toggle="dropdown" data-text="主贴(7506)">主贴<b class="caret"></b></a><ul class="dropdown-menu"><li><a href="#status_content" data-toggle="tab" data-type="" data-text="主贴">主贴</a></li><li><a href="#status_content" data-toggle="tab" data-type="0" data-text="原发布">原发布</a></li><li><a href="#status_content" data-toggle="tab" data-type="1" data-text="带标题">带标题</a></li><li><a href="#status_content" data-toggle="tab" data-type="2" data-text="长文章">长文章</a></li><li><a href="#status_content" data-toggle="tab" data-type="3" data-text="交易">交易</a></li></ul></li><li><a href="#favs_content" data-toggle="tab">收藏<small id="favsCount"></small></a></li><li><a href="#friends_content" data-toggle="tab">关注(647)</a></li><li><a href="#followers_content" data-toggle="tab">粉丝(200893)</a></li></ul></div><div class="statuses_container container tab-content"><div id="status_content" class="status_content container active tab-pane"><div class="status_bd"><div id="statusLists" class="allStatuses no-head"></div></div><div class="status_widget"><div class="seachbar"><input id="searchStatus" type="text" autocomplete="off" placeholder="搜索他的讨论" class="placeholder"/><span class="glass"><i></i></span></div><style>.mentionedStocks{
  margin-top:15px;
  display:none;
}
.stocksList{
  border-top:1px solid #F1F1F1;
  margin-top: 8px;
  padding-top: 10px;
  font-size:12px;
}
.stocksList .stockInfo{
  display:inline-block;
  margin-right:5px;
  margin-bottom:8px;
}
.stocksList .stockInfo span{
  color:#888;
  cursor:pointer;
}
</style><div class="mentionedStocks"><h2 class="widget-title">他经常讨论的股票 </h2><div class="fixit"></div><div class="stocksList"></div><div class="fixit"></div><script>seajs.use("SNB.base.js", function(){
  var uid = 6785033954;
  SNB.get("/user/top_status_count_stock.json", { count: 5, uid: uid }, function(stocks){
    if ( stocks && stocks.length ) {
      var html = "";
      _.each(stocks, function(stock, index){
        if ( stock.status_all_count > 0 ) {
          var count = stock.status_all_count,
            name = stock.stockName,
            symbol = stock.symbol,
            title = name + "(" + symbol + ") 查看" + count + "条讨论";
            
          html += '<span class="stockInfo" title="' + title + '" data-name="' + name + '" data-symbol="' + symbol + '" data-count="' + count + '"><a href="#">' + name + '</a><span>(<span class="status_count">' + count + '</span>条讨论)</span></span>';
        }
      });
      if ( html ) {
        $(".mentionedStocks .stocksList").append(html);
        $(".mentionedStocks").show();
      }
    }
  })
})</script></div></div></div><div id="favs_content" class="fade tab-pane"></div><div id="friends_content" class="fade tab-pane"></div><div id="followers_content" class="fade tab-pane"></div></div><style>.seachbar .glass {
  padding:0;
}
.seachbar .glass i{
  background-position:-172px -1px
}</style><script>(function($){
  SNB.data.req_isBrick = 0;
  SNB.data.statuses = {"total":7504,"maxPage":376,"count":20,"statuses":[{"id":23952666,"user_id":6785033954,"title":"","created_at":1369411591000,"retweet_count":3,"reply_count":2,"fav_count":2,"truncated":false,"commentId":21807447,"retweet_status_id":23881062,"symbol_id":null,"description":"1.是五粮液最用心、投资最大的新品。2.是第一个直接挑战洋酒的中国品牌。3.是第一个兼容性极强的高度果酒4.是第一个开创馥郁香型的新品类5.是五粮液集团董事级酿酒大师陈林、书记级酿酒大师林红,历时十多年,上百种配方筛选,上千次的酿造实验,才诞生了冰珀43。","type":null,"source_link":null,"edited_at":null,"pic":null,"user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":{"id":23881062,"user_id":6785033954,"title":"冰珀43——中国首席夜场酒品牌","created_at":1368794422000,"retweet_count":47,"reply_count":73,"fav_count":18,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"到现在没人关心五粮液花重资精心打造的冰珀43，这真是一款无足轻重的品牌吗，恰恰相反，我认为冰珀43是五粮液开辟夜场酒市场和国际市场的利剑，在五粮液整个战略布局中起着相当关键的作用。中国白酒一直打不开国际市场很大的原因就是，不时尚，中国白酒文化无法被外国人所接受。缺乏时尚元素的中国...","type":"3","source_link":null,"edited_at":1369411673000,"pic":"http://xqimg.imedao.com/13eb280637d303fe6781bf91.jpg!thumb.jpg,http://xqimg.imedao.com/13ed74b5d144e3fea512b3cf.jpg!thumb.jpg,http://xqimg.imedao.com/13eb274ea39283fb7a78788b.jpg!thumb.jpg,http://xqimg.imedao.com/13ed74bc79e443fdeffef0ff.jpg!thumb.jpg","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23881062","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":0,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-17 20:40","expend":true,"canEdit":true,"firstImg":"http://xqimg.imedao.com/13eb280637d303fe6781bf91.jpg!thumb.jpg","topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"到现在没人关心五粮液花重资精心打造的冰珀43，这真是一款无足轻重的品牌吗，恰恰相反，我认为冰珀43是五粮液开辟夜场酒市场和国际市场的利剑，在五粮液整个战略布局中起着相当关键的作用。中国白酒一直打不开国际市场很大的原因就是，不时尚，中国白酒文化无法被外国人所接受。缺乏时尚元素的中国白酒做出的夜场酒居然不输任何一款世界顶级美酒，这是让我想不到的。<br><br>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;五粮液冰珀43是五粮液集团唐桥董事长亲自推荐，五粮液集团董事陈林和果酒大师林红通过12年不懈努力，亲自研发的酒，无论是它的出生还是品质都是补充高端缺口最佳第一选择。对于冰珀43的发展，五粮液集团唐桥董事长坚定地表示：“冰珀43是五粮液集团针对夜场打造的唯一高端战略品牌，我们要打造最优质的美酒，诠释中国人最深的敬意！再创一个百亿品牌神话！”<br><br>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;仅采用冰酒低温发酵技术、白兰地蒸馏技术还不够，口感的关键在于配方，再好的果酒原浆，如果配方不够好，都会影响酒的风味。为创造出独傲群雄的稀有口感，冰珀研发团队尝试了上百种配方，历经上千次试酿，才使得冰珀43入口非常柔和，花果芬芳一下子就融化在嘴里，如行春郊，如梦如醉，醉的舒服，醉的恰如其分，次日还不会一身酒气。法国品酒大师团盲品后，不能相信口感第一的酒，居然来自中国，连声赞叹：“东方白兰地，神奇的黄金液体！”<br><br>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;中国夜场酒一年至少有3000亿的市场份额，一直以来都被洋品牌所垄断。洋酒渠道混乱，整个市场对洋酒的消费信心有疑虑。经过12年的酝酿，冰珀43上市短短数月，得到了所有夜店老板的支持，90%以上的老板表示要亲自来抓，超过50%的老板有做分销商的意愿，在地级市场单店就能销售200瓶—500瓶，而洋酒十几个品牌共卖不到两百瓶。全国市场的红火销售是指日可待！<br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13eb280637d303fe6781bf91.jpg!custom.jpg\" /><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ed74b5d144e3fea512b3cf.jpg!custom.jpg\" /><br><br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13eb274ea39283fb7a78788b.jpg!custom.jpg\" /><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ed74bc79e443fdeffef0ff.jpg!custom.jpg\" /><br><br><br><a href=\"http://www.wlybp43.com\" title=\"http://www.wlybp43.com\"  target=\"_blank\">http://www.wlybp43.com</a><br>五粮液冰珀43—全国运营中心<br><br><a href=\"http://www.56.com/u92/v_ODQwNDExMzc.html\" title=\"http://www.56.com/u92/v_ODQwNDExMzc.html\"  target=\"_blank\">http://www.56.com/u92/v_ODQwNDExMzc.html</a><br>冰珀43——东方白兰地","source":"雪球"},"target":"/6785033954/23952666","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":300,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-25 00:06","expend":false,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"1.是五粮液最用心、投资最大的新品。2.是第一个直接挑战洋酒的中国品牌。3.是第一个兼容性极强的高度果酒4.是第一个开创馥郁香型的新品类5.是五粮液集团董事级酿酒大师陈林、书记级酿酒大师林红,历时十多年,上百种配方筛选,上千次的酿造实验,才诞生了冰珀43。","source":"雪球"},{"id":23928430,"user_id":6785033954,"title":"","created_at":1369229499000,"retweet_count":1,"reply_count":4,"fav_count":3,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"<a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a> 中信国健王俊林：随着国家对慢性病的越发重视，部分地区已将相关药物纳入了基本药物目录。类风湿性关节炎作为一种较常见的慢性病，也受到很大关注。作为国内上市的首个治疗类风湿关节炎药物--益赛普，目前已进入了部分城市医保，但由于与相关部门沟通较晚，并没有全面进入医...","type":"0","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23928430","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":321,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 21:31","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a> 中信国健王俊林：随着国家对慢性病的越发重视，部分地区已将相关药物纳入了基本药物目录。类风湿性关节炎作为一种较常见的慢性病，也受到很大关注。作为国内上市的首个治疗类风湿关节炎药物--益赛普，目前已进入了部分城市医保，但由于与相关部门沟通较晚，并没有全面进入医保。我们努力争取益赛普能进入到下一轮国家、省级医保目录，尽快减轻更多病人的负担。","source":"雪球"},{"id":23928345,"user_id":6785033954,"title":"中信国健王俊林：日常点滴汇聚企业社会责任","created_at":1369229052000,"retweet_count":3,"reply_count":1,"fav_count":4,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":" 编者按：5月16日，上海中信国健药业股份有限公司首次面向公众发布《2012年年度企业社会责任报告》。作为民族药企，中信国健以开放、透明、积极的姿态向社会公开承担社会责任。中信国健总经理王俊林先生在报告致辞：“历经十余年的发展，中信国健已成功建立了国内领先的抗体药物开发和产业化生产平...","type":"3","source_link":null,"edited_at":1369229165000,"pic":"http://xqimg.imedao.com/13ecc684a941293fc1458c8f.png!thumb.jpg,http://xqimg.imedao.com/13ecc68e44a12b3fe95d9ef2.png!thumb.jpg","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23928345","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":474,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 21:24","expend":true,"canEdit":true,"firstImg":"http://xqimg.imedao.com/13ecc684a941293fc1458c8f.png!thumb.jpg","topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ecc684a941293fc1458c8f.png!custom.jpg\" /><br><br>编者按：5月16日，上海中信国健药业股份有限公司首次面向公众发布《2012年年度企业社会责任报告》。作为民族药企，中信国健以开放、透明、积极的姿态向社会公开承担社会责任。中信国健总经理王俊林先生在报告致辞：“历经十余年的发展，中信国健已成功建立了国内领先的抗体药物开发和产业化生产平台，这种领先不仅体现在强大的科研能力和销售业绩上，更体现在对中国市场的前瞻性思考和企业社会责任的持续关注上。”<br><br>作为国内抗体药物企业领军者，中信国健对中国市场的前瞻性思考和企业社会责任的持续关注具体如何体现？近日，生物谷专访中信国健总经理王俊林先生，他就企业社会责任、药品质量控制、创新研发、新产品方向及市场战略等问题作了全面解读。<br><br>问：您如何看待药企所应该承担的社会责任？<br><br>王俊林：企业离不开社会。企业社会责任涉及到的利益相关者很广，除了企业在创造利润，对股东负责以外，还承担着对公司员工、医生、患者、供应商、社区和环境的责任。所以企业的价值应该体现在承担社会责任上，作为国内制药企业的创新引领者，中信国健一直在用实际行动将社会责任落实到日常经营行为。<br><br>具体来说，比如在节能环保方面，中信国健不惜以高价引进低能耗的“汽水分离设备”；塑料制品外包装选择方面，可降解的塑封材料成本比不可降解的塑封材料贵很多，但是为了社会环境问题，可降解塑封材料成为了我们的首选；我们也有意识地培养员工环保意识，员工日常办公打印用纸，均采用双面打印，以节约资源。而谈到对于社会的责任，中信国健一直积极投身社会慈善公益活动。比如，连续三年开展“患者关爱工程”，捐助300万元左右药品，为150余名贫困风湿病患者提供免费规范治疗，为超过2万名风湿病患者提供免费的专家疾病咨询及健康资料，分发患教手册约40余万册；2013年，中信国健还与民政局中国健康促进基金会专门设置了赠药慈善活动项目，目的是为了减轻因病致贫家庭的社会问题。<br><br>问：2013年度，中信国健在社会责任管理方面会有哪些新举措？<br><br>王俊林：我们希望将历年所做的企业社会责任的项目再深入、细致地执行下去。今年，中信国健在员工发展方面将开展全新工作。我们将更多致力于员工职业素养的培养，凝聚力的增强， 并深入地考虑员工的需求，在注重员工绩效的同时，更加关注员工的个人能力在企业全方位的提升与发展。<br><br>问：药品质量控制一直是制药厂商最为关注的部分。对于国内生物制药企业而言，面临的最大挑战是什么？能否分享一下中信国健在药品质量控制管理方面的经验？<br><br>王俊林：您这个问题问得非常好。质量是制药企业生存的根本，也是企业存亡的红线。药品质量控制的提升是一项长期工作，需要企业循序渐进地开展，持续地推进。<br><br>当前，国内生物制药企业面临最大的挑战是人才。我们中信国健的人才必须具备以下两种：一类是具备专业背景，同时拥有不断改进质量意识的人才。因为对于参与质量控制的人而言，如果将达标作为最终的标准，这将会非常危险。另外一类是具备国际化视野，善于沟通交流，并乐于挑战现有问题的人才。<br><br>质量保证、分析和研发团队是中信国健药品质量控制的“三驾马车”。质量保证团队严格按照CFDA的标准生产合格产品，负责整个生产环节的监管，确保产品符合工艺规程标准；质量分析团队负责分析生产过程中所设置的1000余个质控点，纠正了从原材料到成品的过程中可能出现的偏差；质量研发团队是中信国健产品不断接近国际标准的生力军。2012年初，中信国健正式启动了质量提升5年计划，争取5年内，在现场生产、质量管理方面，水平达到美欧国家的《药品生产质量管理规范》的标准。<br><br>整个质量团队得益于我们优秀的产品基础。同时，产品的国际化步伐也促使了质量的提升。中信国健的产品在获取海外认证的过程中，包括巴西、南非、土耳其、乌克兰等国家的相关工作人员对中信国健工厂审计时，他们会对产品质量提出各种要求，我们在满足其要求的同时，也进一步促使了产品质量的提升。<br><br>问：益赛普是中信国健的拳头产品，但目前国内也有一些类似产品陆续上市。对此，中信国健有什么策略？另外，益赛普已经进入一些城市的医保，对此公司作了哪些策略调整？<br><br>王俊林：益赛普是国内第一家上市的，也是国内企业自主研发的生物制剂。过去八年时间里，中信国健引领了中国风湿领域学科的发展，尤其是在生物制剂的使用方面。正如你所言，辉瑞、强生、雅培等风湿领域的生物制剂产品陆续在国内上市，同时本土企业也有几款上市和待上市的产品。<br><br>从整个生物制剂的大市场来看，国外的生物制剂的使用率已经达到了40%，但是国内还不足10%，其发展空间巨大。具体到风湿领域市场，我国每年有超过1000万的风湿病病人，即使包括即将上市的产品，也仅能满足其中的几十万人的需求。<br><br>面对如此广阔的市场空间，与国内外其他药企联合，共同培育市场才是中信国健的应对之道。与其说是竞争，不如说是共赢。<br><br>随着国家对慢性病的越发重视，部分地区已将相关药物纳入了基本药物目录。类风湿性关节炎作为一种较常见的慢性病，也受到很大关注。作为国内上市的首个治疗类风湿关节炎药物--益赛普，目前已进入了部分城市医保，但由于与相关部门沟通较晚，并没有全面进入医保。我们努力争取益赛普能进入到下一轮国家、省级医保目录，尽快减轻更多病人的负担。<br><br>问：在风湿治疗领域，如何与竞争对手合作共赢？<br><br>王俊林：用心做学术。也就是说：与其他药企共同帮助医生和专家获取临床数据，通过数据分析，针对不同患者的情况，具体分析是否需要用药。多年来，中信国健坚持与临床医生共同合作，开展了大量的临床项目，投入了大量资源。主要工作包括：普及教育医生对病人开展影像学分层诊治；与中国医师协会合作，开展对基层医院医生的培训，完善医院风湿科室等。<br><br>与化学药相比，生物制剂对部分疾病治疗更具优势，但在价格上存在劣势。让临床医生与病人充分认识到生物制剂在治疗方面的优势，还需要大家共同努力。<br><br>所谓共赢，即与竞争对手一起将学术推广开展的更深更广。从浅海走向深海，从三线医院到二线医院再到一线医院，帮助医生更准确的用药，也让病人有更好的选择与判断。<br><br>问：目前，健尼哌的市场情况如何？<br><br>王俊林：由于器官移植的手术量不多，健尼哌的整体市场并不大。目前，健尼哌占据国内约30-40%的市场份额。<br><br>问：之前您分享了中信国健在药品质量控制方面的研发，另外，中信国健从上游研发到下游工艺也作出了大量创新。请问您是如何理解创新的？接下来，中信国健又将会有怎样的创新？<br><br>王俊林：首先，要明确创新是一个很丰富的概念。多数人理解的“创新”主要集中在基础研究领域。比如，筛选出一个全新的化合物。这部分容易出创新成果，也容易让大家理解。但制药企业将基础研究的成果，通过临床验证、工艺开发转化成可安全使用的药物，这本身也是创新过程，甚至包括药物销售过程，也不乏创新活动。许多人忽视了这类创新。<br><br>其次，国外大型制药企业投入大量资金从事新药研发，这并不适合于当下国内药企的发展现状。每年投入数十亿美金用于新药研发，成功上市者了了，多数被丢弃。这对于国内药企而言，难以承受。个人认为：“跟随”是一个比较理性的、清醒的创新选择。公司创建类似一个“情报”系统，专门监控国外“新药”，尤其是已做到二期临床、三期临床的“新药”，如果新药临床效果很好，并能够规避一些“陷阱”风险，可绕过知识产权的障碍，在此基础上开发出更好的药物，这或许是目前中国企业比较理性且现实的选择。<br><br>中信国健的创新策略类似于此。大概前十年，中信国健通过“跟随”解决了生存问题，之后一段时间 “跟随”还会继续；另外，我们将选择全新的领域、国际专利，展开全新的研发。这也是中信国健当前对于“创新”的选择。<br><br>问：目前中信国健研发投入占销售额的比例是多少？您刚才提到的选择全新的领域，展开全新研发，能否透露具体方向？<br><br>王俊林：早年还没有实现销售额时，中信国健研发投入大概是每年五、六千万。目前研发的投入已经超过了销售额的10%。<br><br>从产品的上游研发到成品销售的整个链条，中信国健已经完全打通。中信国健下一步将开发怎样的产品，我们会凭借对市场的熟识度，从市场的角度去考虑布局与安排。红斑狼疮、干燥综合征等自身免疫性疾病对人体健康威胁大，患者群体庞大，但传统药物市场没有较好的药物控制病情，它将会是中信国健药品开发的重要方向。此外，肿瘤领域受关注度居高不下，虽然中信国健在治疗乳腺癌方面已有很好的药物，但它只针对三分之一的乳腺癌病人，另外三分之二的乳腺癌病人，我们能否为其提供更好的药物呢？这也将是未来中信国健药品开发的重要方向。<br><br>问：近日，安进与浙江贝达药业拟建立一合资公司，为中外合资的公司再&#34;添砖加瓦&#34;；另外，跨国生物制药企业陆续在国内建立研发中心。这些将给中信国健带来了怎样的机遇和挑战？<br><br>王俊林：国内企业与外资企业、内资企业之间的合作，有成功的案例。但也有因为在管理控制权方面问题，失败的例子。<br><br>我认为合作目的在于优势互补。国内企业的销售力、市场熟悉度优于国外企业，而国外企业优秀的产品、独到的工艺是多数国内企业缺乏的。彼此合资或合作，则具有较强的互补性。<br><br>中信国健拥有专业的市场拓展渠道、良好的生产体系，我们更倾向于与国外的企业在研发、新产品的寻找方面尝试沟通。合作重点不是将国外的产品引到中国来，而是如何借助国外公司将中信国健的产品带到国外去。这已经有了不少案例。另外，中信国健还希望与具备海外销售力的企业开展沟通合作，甚至包括投资国外较好的研发项目，共同运作，打开并培育这一市场。<br><br>问：您担任中信国健总经理以来个人感触最深的地方是什么？<br><br>王俊林：主要有两点。第一，坚持一定会有回报，要有足够的耐心。一个药物从研发到大规模生产，动辄十几年，且伴随高风险，需要管理者具备足够耐心。<br><br>另一个是药品的上市，会带来&#34;成就感&#34;，这里的&#34;成就感&#34;不是企业赚了多少钱，也不是企业有多大规模，而是看到很多医生有诊治这些疾病的信心，医生有很好的工具可以解决疾病问题；还有很多病人，几十年的痛苦，用到生物制剂以后好像一下子人就解放了：比如我们很多的病人，以前都是推着轮椅的，而他们现在可以站起来了，与正常人一样可以生活；还有很多银屑病人好像二十几年都被疾病绑住无法正常生活，用了生物制剂后，改变这样的生存状态，比如我们待上市的肿瘤药物，在临床用药阶段就收到很多病人的感谢信，我想这些是一个制药企业管理者最大的成就感，我们能为患者带来的实实在在的改善，为社会解决问题。<br><br>问：作为是生物制药行业的领军者，中信国健将如何培育行业的生态链？<br><br>王俊林：谈到健康的生态链，它应该是有草地、灌木、乔木。中信国健希望成为里面的乔木。随着更多企业进入到这一领域，行业会进入整理阶段，这将会是一个从无序到有序的过程。<br><br>乔木不会太多，快速成长很重要。中信国健需要迅速成长为“乔木”。这要求自身是一家规模化生产的企业；可以开发针对市场需求的产品，批量化生产药物。当然，中信国健拥有自己的研究院，所开发的技术既为中信国健服务，也为整个行业平台服务，我们非常愿意与行业朋友共同加速整个行业的发展。<br><br>&lt;版权所有，转载请注明来源。为了最大限度地保护本文涉及到的人物（采访对象或原始作者）的隐私权，其联系方式不公开，读者如果有任何学术或商业上的交流愿望或咨询需求，请联系生物谷(editor@bioon.com)代为转达。&gt;<br><br>关于王俊林先生<br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ecc68e44a12b3fe95d9ef2.png!custom.jpg\" /><br>王俊林先生<br><br>2002年至今：上海中信国健药业有限公司常务副总、执行总裁，上海中信国健生物技术研究院院长<br>1999年至2002年，上海兰生上科创业投资公司投资部经理<br>1995年至1999年，上海科学院<br>1990年至1995年， 复旦大学<br><br>个人荣誉：<br><br>2010年4月：上海市劳动模范<br>2009年7月：上海市浦东新区人大代表<br>2005年：上海市浦东新区十大杰出青年提名<br>2002年：上海市科技领军人物<br><br>关于上海中信国健药业股份有限公司<br><br>上海中信国健药业股份有限公司(CPGJ)是由中国中信集团有限公司和上海兰生国健药业有限公司共同投资的生物医药高新技术企业，专注于抗体药物的研发、中试和产业化，现已成为国内抗体药物企业的领军者，提供覆盖抗肿瘤、移植、自身免疫系统等重大疾病领域的靶向药物。作为亚洲规模最大的哺乳动物细胞培养生产基地之一，公司拥有国内最先进的3条750升、2条3000升的真核细胞培养生产线；同时，6条符合欧盟标准的5000升生产线正在建设中。公司还特别设计建立了涵盖影响药品质量所有因素，包括物料管理、生产管理、质量控制、质量保证、设备设施和包装标签的完善质量管理体系，其3000升生产线采用了具有国际领先水平的现场总线控制系统(FCS)以及过程控制系统(PCS)，该系统运用到的Delta VTM 数字自动化技术，对药品的整个生产过程进行严密地不间断地监测，最大程度地消除产品质量隐患和潜在的质量风险。更多详情，请查看：<a href=\"http://www.cpgj-pharm.com\" title=\"http://www.cpgj-pharm.com\"  target=\"_blank\">http://www.cpgj-pharm.com</a>。<br><br><a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a>","source":"雪球"},{"id":23927728,"user_id":6785033954,"title":"","created_at":1369224553000,"retweet_count":5,"reply_count":3,"fav_count":2,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"<a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a> 据国际知名咨询公司统计，单抗药物未来十年复合增长率将要达到56%。做为中国抗体药物领军企业中信国健复合增长率能达到多少？十年复合增长率达到56%意味着十年增长85.36倍。可见十年后中信国健会达到一个怎样的高度。","type":"0","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23927728","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":333,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 20:09","expend":false,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a> 据国际知名咨询公司统计，单抗药物未来十年复合增长率将要达到56%。做为中国抗体药物领军企业中信国健复合增长率能达到多少？十年复合增长率达到56%意味着十年增长85.36倍。可见十年后中信国健会达到一个怎样的高度。","source":"雪球"},{"id":23927639,"user_id":6785033954,"title":"","created_at":1369223933000,"retweet_count":1,"reply_count":1,"fav_count":3,"truncated":false,"commentId":21791191,"retweet_status_id":23927598,"symbol_id":null,"description":"据国际知名咨询公司统计，在2015年将有640亿美元生物药物专利到期，又将给世界生物仿制药的发展提供巨大的成长空间，预测到2020年将要到达2000多亿美元，未来十年复合增长率将要达到56%。如此巨大的市场为拥有核心技术、产业化水平高、市场销售渠道好的生物制药公司带来了机会。生物仿制药的前景很...","type":null,"source_link":null,"edited_at":null,"pic":null,"user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":{"id":23927598,"user_id":6785033954,"title":"生物仿制药研发的“三把利剑”","created_at":1369223537000,"retweet_count":3,"reply_count":3,"fav_count":5,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"上海 2013年5月21日电 /生物谷BIOON/ --医药产业正在经历以生命科学为主导的第三次工业革命，生物仿制药逐渐成为新兴的价值高峰。目前，全世界各国政府都在竭力控制医药卫生费用的过快增长，鼓励仿制药的发展。据国际知名咨询公司统计，在2015年将有640亿美元生物药物专利到期，又将给世界生物仿制...","type":"3","source_link":null,"edited_at":1369223981000,"pic":"http://xqimg.imedao.com/13ecc14576e1283fdc9ce418.jpg!thumb.jpg,http://xqimg.imedao.com/13ecc14508b1243fdd5f36b4.jpg!thumb.jpg,http://xqimg.imedao.com/13ecc1450fc1263fd1996a28.jpg!thumb.jpg","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23927598","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":0,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 19:52","expend":true,"canEdit":true,"firstImg":"http://xqimg.imedao.com/13ecc14576e1283fdc9ce418.jpg!thumb.jpg","topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"上海 2013年5月21日电 /生物谷BIOON/ --医药产业正在经历以生命科学为主导的第三次工业革命，生物仿制药逐渐成为新兴的价值高峰。目前，全世界各国政府都在竭力控制医药卫生费用的过快增长，鼓励仿制药的发展。据国际知名咨询公司统计，在2015年将有640亿美元生物药物专利到期，又将给世界生物仿制药的发展提供巨大的成长空间，预测到2020年将要到达2000多亿美元，未来十年复合增长率将要达到56%。如此巨大的市场为拥有核心技术、产业化水平高、市场销售渠道好的生物制药公司带来了机会。<br><br>生物仿制药全球形势喜人<br><br>中国是仿制药生产和使用的大国，生物制药产值在医药总产值中的比重从2006年的7.91%升至2011年的16.1%，其中生物制药在医药市场的份额多由大品种驱动。近年国家在生物技术方面给予越来越多的关注和重视，单抗药物研究已被列为国家&#34;十二五计划&#34;和国家重点攻关项目、新药重大创制项目等。对于高端的生物仿制药，如抗体类药物，目前被认为是生物仿制药领域附加值最大的产品，制备工艺复杂、产业化投入大，进入风险高、资金投入需求大、竞争者相对较少。在5月14-16日举办的2013生物制药周中，与会嘉宾就在中国开发生物仿制药的技术层面核心技术进行了深入的交流和探讨。<br><br>生物仿制药开发技术门槛&#34;惊人&#34;<br><br>1、高表达细胞株和细胞培养工艺开发。<br><br>当前，哺乳动物细胞表达成为生物药物生产的重要技术。在2008年1月到2011年6月灭国FDA批准的27个生物药物中，18个是重组蛋白，其中12个是采用哺乳动物细胞表达技术生产的。哺乳动物细胞表达技术的瓶颈和核心问题是实现工程细胞的高活性生长和长期表达。上世纪80年代，批次培养方式只能连续培养7d，细胞密度约为1-2×106ml，单位产量和体积产量为12-20pg/cell/d和50-100 mg/L，而当前的流加培养方式可以连续培养21d，细胞密度达到1-15×107 ml，单位产量和体积产量可分别达到50-90pg/cell/day和1-5 g/L，产量获得了巨大的提升。其中的核心技术就是高表达细胞株构建和高效的动物细胞培养工艺开发。<br><br>动物细胞培养工艺开发技术是抗体药物生产的关键环节，目前细胞培养主流工艺是流加培养，在流加培养过程中，一次性反应器和高效无血清培养基的使用是保证产量和良好质量的关键。<br><br>上海复宏汉霖生物技术有限公司总裁刘世高在讲座中表示，一次性生物反应器通常使用生物兼容性高的特殊塑料制造，成本低，可有效避免交叉污染，由于这一系列优点已经取代传统不锈钢反应器应用于生物制药的生产形式多样，目前的工作体积已经到达上千升，具有良好的应用前景，成为了生物药物开发的一个趋势。<br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ecc14576e1283fdc9ce418.jpg!custom.jpg\" /><br><br>甘肃万洲健顺生物科技有限公司的罗顺总裁在报告中指出，动物细胞无血清培养基是细胞工艺开发中的关键部分，良好的培养基应该有利于细胞高活性高密度正确表达目的蛋白，并利于下游产品纯化和检测。提供可靠。稳定和高质量的培养基在全世界一直都是挑战，使用现代化的平台高通量筛选技术能有效地模拟细胞的生长状态，在短时间内优化培养条件，选择良好的生长工艺。<br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ecc14508b1243fdd5f36b4.jpg!custom.jpg\" /><br><br>2、蛋白纯化工艺和过程控制。<br><br>上海交通大学李荣秀教授在会议中指出，生物药物高达80%的制造成本来源于纯化过程，纯化过程的总指导原则是总生产步骤要尽量少，每步收率要尽量高，保证产品质量，降低成本，使用QbD的理念进行蛋白药物的纯化有着至关重要的意义。<br><br>李教授介绍了利用现代分子设计和合成技术发展的稳定小分子放生亲和配基的特点，具有易于合成和纯化，成本低廉，生物和化学性质稳定，能经受在线清洁和消毒灯优点，是降低蛋白纯化成本的良好选择。<br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ecc1450fc1263fd1996a28.jpg!custom.jpg\" /><br><br>在生物药物开发过程中，要利用QbD质量源于设计的理念，注意工艺参数变动范围和设计空间：产品质量和产率是过程工艺的函数，需要尽可能接近真实，满足产品产率和关键质量属性CQAs要求的过程关键工艺参数要尽可能接近理想状态。<br><br>PAT（Process analytical technology）过程分析技术目前在欧美大型生物制药公司工艺开发过程中得到了一致认可和使用，PAT包括风险分析、过程分析、过程控制工具、实验设计和多元数据分析。PAT是对工艺的理解和优化，在研发新产品、产品改造以及完善产品工艺过程中有着重要的作用。赛多利斯中国市场总监王旭宇女士在会议中介绍了生物制药工艺中的试验设计与过程控制，并用实际例子解释了DoE实验设计的理念与工艺参数等内容，对开发稳健高效经济的抗体药物生产工艺具有良好的指导意义。<br><br>3、抗体药物质量标准<br><br>生物药物开发过程中的生产工艺和质量控制具有很强的科技型，复杂性和挑战性，全面质量控制策略是保证生产的生物制药产品具有稳定可接受的质量水平，并在整个货架期保持质量稳定。在生物制药过程中，&#34;遗传改变了的生物体&#34;&#34;复杂的，多步骤的，长期的生产周期&#34;&#34;广泛的在线检测与分析&#34;是描述一个生物制药过程时常用的短语，生物仿制药开发过程中，质量标准的建立和控制是至关重要的一部分。在生物药研发质量控制过程中，尤其需要强调表达构建研究，细胞基质研究，原料的选择，生产认证研究和设施控制等几个方面。<br><br>生物仿制药法规政策&#34;急人&#34;<br><br>欧盟生物仿制药政策最早得到完善，已于2005年出台《生物仿制药指导原则》，2006～2010年陆续出台9个细分领域的指导守则，现已有7个生物仿制药上市；而美国已于两个星期前出台了新的针对生物仿制药的法规；日本、韩国、加拿大、WHO等国家和组织参照欧盟，相继出台了生物仿制药申请指导原则。目前中国生物仿制药开发主要参考FDA，EMA，ICH关于生物药物开发原则和指南，国内目前已有大量生物仿制药上市，但还没有明确的生物仿制药法规。<br><br>我国抗体类药物的市场化刚刚起步，主要表现为工艺水平不高，产业化规模较小，相关科技人才不足，缺乏核心技术，产学研脱节等。鉴于国内企业纷纷上马生物仿制药项目，急需良好的药物研发指导原则，因此中国生物仿制药法规的早日出台对规范国家生物仿制药行业发展，促进产学研投资机构的积极性至关重要。<br><br>开发生物仿制药已经是未来几年医药行业的趋势，&#34;识时务者为俊杰&#34;，学术界和工业界对生物仿制药的开发技术进行广泛深入的交流探讨对行业的良好发展具有极大的推进作用。生物仿制药的前景很美好，同时也面临着极为严峻的技术和资金挑战，谁能最终在这场&#34;没有硝烟的战争&#34;中胜出，我们拭目以待。（生物谷Bioon.com）<br><br>(责任编辑：lili.zhao)<br><br><a href=\"http://xueqiu.com/S/PRE317\"   target=\"_blank\">$中信国健(PRE317)$</a> <a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a>","source":"雪球"},"target":"/6785033954/23927639","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":279,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 19:58","expend":true,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"据国际知名咨询公司统计，在2015年将有640亿美元生物药物专利到期，又将给世界生物仿制药的发展提供巨大的成长空间，预测到2020年将要到达2000多亿美元，未来十年复合增长率将要达到56%。如此巨大的市场为拥有核心技术、产业化水平高、市场销售渠道好的生物制药公司带来了机会。生物仿制药的前景很美好，同时也面临着极为严峻的技术和资金挑战，谁能最终在这场&#34;没有硝烟的战争&#34;中胜出，我们拭目以待。","source":"雪球"},{"id":23927605,"user_id":6785033954,"title":"","created_at":1369223624000,"retweet_count":0,"reply_count":0,"fav_count":0,"truncated":false,"commentId":21791159,"retweet_status_id":23927598,"symbol_id":null,"description":"近年国家在生物技术方面给予越来越多的关注和重视，单抗药物研究已被列为国家&#34;十二五计划&#34;和国家重点攻关项目、新药重大创制项目等。对于高端的生物仿制药，如抗体类药物，目前被认为是生物仿制药领域附加值最大的产品，制备工艺复杂、产业化投入大，进入风险高、资金投入需求大、竞争者相...","type":null,"source_link":null,"edited_at":null,"pic":null,"user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":{"id":23927598,"user_id":6785033954,"title":"生物仿制药研发的“三把利剑”","created_at":1369223537000,"retweet_count":3,"reply_count":3,"fav_count":5,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"上海 2013年5月21日电 /生物谷BIOON/ --医药产业正在经历以生命科学为主导的第三次工业革命，生物仿制药逐渐成为新兴的价值高峰。目前，全世界各国政府都在竭力控制医药卫生费用的过快增长，鼓励仿制药的发展。据国际知名咨询公司统计，在2015年将有640亿美元生物药物专利到期，又将给世界生物仿制...","type":"3","source_link":null,"edited_at":1369223981000,"pic":"http://xqimg.imedao.com/13ecc14576e1283fdc9ce418.jpg!thumb.jpg,http://xqimg.imedao.com/13ecc14508b1243fdd5f36b4.jpg!thumb.jpg,http://xqimg.imedao.com/13ecc1450fc1263fd1996a28.jpg!thumb.jpg","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23927598","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":0,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 19:52","expend":true,"canEdit":true,"firstImg":"http://xqimg.imedao.com/13ecc14576e1283fdc9ce418.jpg!thumb.jpg","topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"上海 2013年5月21日电 /生物谷BIOON/ --医药产业正在经历以生命科学为主导的第三次工业革命，生物仿制药逐渐成为新兴的价值高峰。目前，全世界各国政府都在竭力控制医药卫生费用的过快增长，鼓励仿制药的发展。据国际知名咨询公司统计，在2015年将有640亿美元生物药物专利到期，又将给世界生物仿制药的发展提供巨大的成长空间，预测到2020年将要到达2000多亿美元，未来十年复合增长率将要达到56%。如此巨大的市场为拥有核心技术、产业化水平高、市场销售渠道好的生物制药公司带来了机会。<br><br>生物仿制药全球形势喜人<br><br>中国是仿制药生产和使用的大国，生物制药产值在医药总产值中的比重从2006年的7.91%升至2011年的16.1%，其中生物制药在医药市场的份额多由大品种驱动。近年国家在生物技术方面给予越来越多的关注和重视，单抗药物研究已被列为国家&#34;十二五计划&#34;和国家重点攻关项目、新药重大创制项目等。对于高端的生物仿制药，如抗体类药物，目前被认为是生物仿制药领域附加值最大的产品，制备工艺复杂、产业化投入大，进入风险高、资金投入需求大、竞争者相对较少。在5月14-16日举办的2013生物制药周中，与会嘉宾就在中国开发生物仿制药的技术层面核心技术进行了深入的交流和探讨。<br><br>生物仿制药开发技术门槛&#34;惊人&#34;<br><br>1、高表达细胞株和细胞培养工艺开发。<br><br>当前，哺乳动物细胞表达成为生物药物生产的重要技术。在2008年1月到2011年6月灭国FDA批准的27个生物药物中，18个是重组蛋白，其中12个是采用哺乳动物细胞表达技术生产的。哺乳动物细胞表达技术的瓶颈和核心问题是实现工程细胞的高活性生长和长期表达。上世纪80年代，批次培养方式只能连续培养7d，细胞密度约为1-2×106ml，单位产量和体积产量为12-20pg/cell/d和50-100 mg/L，而当前的流加培养方式可以连续培养21d，细胞密度达到1-15×107 ml，单位产量和体积产量可分别达到50-90pg/cell/day和1-5 g/L，产量获得了巨大的提升。其中的核心技术就是高表达细胞株构建和高效的动物细胞培养工艺开发。<br><br>动物细胞培养工艺开发技术是抗体药物生产的关键环节，目前细胞培养主流工艺是流加培养，在流加培养过程中，一次性反应器和高效无血清培养基的使用是保证产量和良好质量的关键。<br><br>上海复宏汉霖生物技术有限公司总裁刘世高在讲座中表示，一次性生物反应器通常使用生物兼容性高的特殊塑料制造，成本低，可有效避免交叉污染，由于这一系列优点已经取代传统不锈钢反应器应用于生物制药的生产形式多样，目前的工作体积已经到达上千升，具有良好的应用前景，成为了生物药物开发的一个趋势。<br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ecc14576e1283fdc9ce418.jpg!custom.jpg\" /><br><br>甘肃万洲健顺生物科技有限公司的罗顺总裁在报告中指出，动物细胞无血清培养基是细胞工艺开发中的关键部分，良好的培养基应该有利于细胞高活性高密度正确表达目的蛋白，并利于下游产品纯化和检测。提供可靠。稳定和高质量的培养基在全世界一直都是挑战，使用现代化的平台高通量筛选技术能有效地模拟细胞的生长状态，在短时间内优化培养条件，选择良好的生长工艺。<br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ecc14508b1243fdd5f36b4.jpg!custom.jpg\" /><br><br>2、蛋白纯化工艺和过程控制。<br><br>上海交通大学李荣秀教授在会议中指出，生物药物高达80%的制造成本来源于纯化过程，纯化过程的总指导原则是总生产步骤要尽量少，每步收率要尽量高，保证产品质量，降低成本，使用QbD的理念进行蛋白药物的纯化有着至关重要的意义。<br><br>李教授介绍了利用现代分子设计和合成技术发展的稳定小分子放生亲和配基的特点，具有易于合成和纯化，成本低廉，生物和化学性质稳定，能经受在线清洁和消毒灯优点，是降低蛋白纯化成本的良好选择。<br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ecc1450fc1263fd1996a28.jpg!custom.jpg\" /><br><br>在生物药物开发过程中，要利用QbD质量源于设计的理念，注意工艺参数变动范围和设计空间：产品质量和产率是过程工艺的函数，需要尽可能接近真实，满足产品产率和关键质量属性CQAs要求的过程关键工艺参数要尽可能接近理想状态。<br><br>PAT（Process analytical technology）过程分析技术目前在欧美大型生物制药公司工艺开发过程中得到了一致认可和使用，PAT包括风险分析、过程分析、过程控制工具、实验设计和多元数据分析。PAT是对工艺的理解和优化，在研发新产品、产品改造以及完善产品工艺过程中有着重要的作用。赛多利斯中国市场总监王旭宇女士在会议中介绍了生物制药工艺中的试验设计与过程控制，并用实际例子解释了DoE实验设计的理念与工艺参数等内容，对开发稳健高效经济的抗体药物生产工艺具有良好的指导意义。<br><br>3、抗体药物质量标准<br><br>生物药物开发过程中的生产工艺和质量控制具有很强的科技型，复杂性和挑战性，全面质量控制策略是保证生产的生物制药产品具有稳定可接受的质量水平，并在整个货架期保持质量稳定。在生物制药过程中，&#34;遗传改变了的生物体&#34;&#34;复杂的，多步骤的，长期的生产周期&#34;&#34;广泛的在线检测与分析&#34;是描述一个生物制药过程时常用的短语，生物仿制药开发过程中，质量标准的建立和控制是至关重要的一部分。在生物药研发质量控制过程中，尤其需要强调表达构建研究，细胞基质研究，原料的选择，生产认证研究和设施控制等几个方面。<br><br>生物仿制药法规政策&#34;急人&#34;<br><br>欧盟生物仿制药政策最早得到完善，已于2005年出台《生物仿制药指导原则》，2006～2010年陆续出台9个细分领域的指导守则，现已有7个生物仿制药上市；而美国已于两个星期前出台了新的针对生物仿制药的法规；日本、韩国、加拿大、WHO等国家和组织参照欧盟，相继出台了生物仿制药申请指导原则。目前中国生物仿制药开发主要参考FDA，EMA，ICH关于生物药物开发原则和指南，国内目前已有大量生物仿制药上市，但还没有明确的生物仿制药法规。<br><br>我国抗体类药物的市场化刚刚起步，主要表现为工艺水平不高，产业化规模较小，相关科技人才不足，缺乏核心技术，产学研脱节等。鉴于国内企业纷纷上马生物仿制药项目，急需良好的药物研发指导原则，因此中国生物仿制药法规的早日出台对规范国家生物仿制药行业发展，促进产学研投资机构的积极性至关重要。<br><br>开发生物仿制药已经是未来几年医药行业的趋势，&#34;识时务者为俊杰&#34;，学术界和工业界对生物仿制药的开发技术进行广泛深入的交流探讨对行业的良好发展具有极大的推进作用。生物仿制药的前景很美好，同时也面临着极为严峻的技术和资金挑战，谁能最终在这场&#34;没有硝烟的战争&#34;中胜出，我们拭目以待。（生物谷Bioon.com）<br><br>(责任编辑：lili.zhao)<br><br><a href=\"http://xueqiu.com/S/PRE317\"   target=\"_blank\">$中信国健(PRE317)$</a> <a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a>","source":"雪球"},"target":"/6785033954/23927605","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":305,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 19:53","expend":true,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"近年国家在生物技术方面给予越来越多的关注和重视，单抗药物研究已被列为国家&#34;十二五计划&#34;和国家重点攻关项目、新药重大创制项目等。对于高端的生物仿制药，如抗体类药物，目前被认为是生物仿制药领域附加值最大的产品，制备工艺复杂、产业化投入大，进入风险高、资金投入需求大、竞争者相对较少。","source":"雪球"},{"id":23927598,"user_id":6785033954,"title":"生物仿制药研发的“三把利剑”","created_at":1369223537000,"retweet_count":3,"reply_count":3,"fav_count":5,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"上海 2013年5月21日电 /生物谷BIOON/ --医药产业正在经历以生命科学为主导的第三次工业革命，生物仿制药逐渐成为新兴的价值高峰。目前，全世界各国政府都在竭力控制医药卫生费用的过快增长，鼓励仿制药的发展。据国际知名咨询公司统计，在2015年将有640亿美元生物药物专利到期，又将给世界生物仿制...","type":"3","source_link":null,"edited_at":1369223981000,"pic":"http://xqimg.imedao.com/13ecc14576e1283fdc9ce418.jpg!thumb.jpg,http://xqimg.imedao.com/13ecc14508b1243fdd5f36b4.jpg!thumb.jpg,http://xqimg.imedao.com/13ecc1450fc1263fd1996a28.jpg!thumb.jpg","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23927598","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":653,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 19:52","expend":true,"canEdit":true,"firstImg":"http://xqimg.imedao.com/13ecc14576e1283fdc9ce418.jpg!thumb.jpg","topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"上海 2013年5月21日电 /生物谷BIOON/ --医药产业正在经历以生命科学为主导的第三次工业革命，生物仿制药逐渐成为新兴的价值高峰。目前，全世界各国政府都在竭力控制医药卫生费用的过快增长，鼓励仿制药的发展。据国际知名咨询公司统计，在2015年将有640亿美元生物药物专利到期，又将给世界生物仿制药的发展提供巨大的成长空间，预测到2020年将要到达2000多亿美元，未来十年复合增长率将要达到56%。如此巨大的市场为拥有核心技术、产业化水平高、市场销售渠道好的生物制药公司带来了机会。<br><br>生物仿制药全球形势喜人<br><br>中国是仿制药生产和使用的大国，生物制药产值在医药总产值中的比重从2006年的7.91%升至2011年的16.1%，其中生物制药在医药市场的份额多由大品种驱动。近年国家在生物技术方面给予越来越多的关注和重视，单抗药物研究已被列为国家&#34;十二五计划&#34;和国家重点攻关项目、新药重大创制项目等。对于高端的生物仿制药，如抗体类药物，目前被认为是生物仿制药领域附加值最大的产品，制备工艺复杂、产业化投入大，进入风险高、资金投入需求大、竞争者相对较少。在5月14-16日举办的2013生物制药周中，与会嘉宾就在中国开发生物仿制药的技术层面核心技术进行了深入的交流和探讨。<br><br>生物仿制药开发技术门槛&#34;惊人&#34;<br><br>1、高表达细胞株和细胞培养工艺开发。<br><br>当前，哺乳动物细胞表达成为生物药物生产的重要技术。在2008年1月到2011年6月灭国FDA批准的27个生物药物中，18个是重组蛋白，其中12个是采用哺乳动物细胞表达技术生产的。哺乳动物细胞表达技术的瓶颈和核心问题是实现工程细胞的高活性生长和长期表达。上世纪80年代，批次培养方式只能连续培养7d，细胞密度约为1-2×106ml，单位产量和体积产量为12-20pg/cell/d和50-100 mg/L，而当前的流加培养方式可以连续培养21d，细胞密度达到1-15×107 ml，单位产量和体积产量可分别达到50-90pg/cell/day和1-5 g/L，产量获得了巨大的提升。其中的核心技术就是高表达细胞株构建和高效的动物细胞培养工艺开发。<br><br>动物细胞培养工艺开发技术是抗体药物生产的关键环节，目前细胞培养主流工艺是流加培养，在流加培养过程中，一次性反应器和高效无血清培养基的使用是保证产量和良好质量的关键。<br><br>上海复宏汉霖生物技术有限公司总裁刘世高在讲座中表示，一次性生物反应器通常使用生物兼容性高的特殊塑料制造，成本低，可有效避免交叉污染，由于这一系列优点已经取代传统不锈钢反应器应用于生物制药的生产形式多样，目前的工作体积已经到达上千升，具有良好的应用前景，成为了生物药物开发的一个趋势。<br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ecc14576e1283fdc9ce418.jpg!custom.jpg\" /><br><br>甘肃万洲健顺生物科技有限公司的罗顺总裁在报告中指出，动物细胞无血清培养基是细胞工艺开发中的关键部分，良好的培养基应该有利于细胞高活性高密度正确表达目的蛋白，并利于下游产品纯化和检测。提供可靠。稳定和高质量的培养基在全世界一直都是挑战，使用现代化的平台高通量筛选技术能有效地模拟细胞的生长状态，在短时间内优化培养条件，选择良好的生长工艺。<br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ecc14508b1243fdd5f36b4.jpg!custom.jpg\" /><br><br>2、蛋白纯化工艺和过程控制。<br><br>上海交通大学李荣秀教授在会议中指出，生物药物高达80%的制造成本来源于纯化过程，纯化过程的总指导原则是总生产步骤要尽量少，每步收率要尽量高，保证产品质量，降低成本，使用QbD的理念进行蛋白药物的纯化有着至关重要的意义。<br><br>李教授介绍了利用现代分子设计和合成技术发展的稳定小分子放生亲和配基的特点，具有易于合成和纯化，成本低廉，生物和化学性质稳定，能经受在线清洁和消毒灯优点，是降低蛋白纯化成本的良好选择。<br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ecc1450fc1263fd1996a28.jpg!custom.jpg\" /><br><br>在生物药物开发过程中，要利用QbD质量源于设计的理念，注意工艺参数变动范围和设计空间：产品质量和产率是过程工艺的函数，需要尽可能接近真实，满足产品产率和关键质量属性CQAs要求的过程关键工艺参数要尽可能接近理想状态。<br><br>PAT（Process analytical technology）过程分析技术目前在欧美大型生物制药公司工艺开发过程中得到了一致认可和使用，PAT包括风险分析、过程分析、过程控制工具、实验设计和多元数据分析。PAT是对工艺的理解和优化，在研发新产品、产品改造以及完善产品工艺过程中有着重要的作用。赛多利斯中国市场总监王旭宇女士在会议中介绍了生物制药工艺中的试验设计与过程控制，并用实际例子解释了DoE实验设计的理念与工艺参数等内容，对开发稳健高效经济的抗体药物生产工艺具有良好的指导意义。<br><br>3、抗体药物质量标准<br><br>生物药物开发过程中的生产工艺和质量控制具有很强的科技型，复杂性和挑战性，全面质量控制策略是保证生产的生物制药产品具有稳定可接受的质量水平，并在整个货架期保持质量稳定。在生物制药过程中，&#34;遗传改变了的生物体&#34;&#34;复杂的，多步骤的，长期的生产周期&#34;&#34;广泛的在线检测与分析&#34;是描述一个生物制药过程时常用的短语，生物仿制药开发过程中，质量标准的建立和控制是至关重要的一部分。在生物药研发质量控制过程中，尤其需要强调表达构建研究，细胞基质研究，原料的选择，生产认证研究和设施控制等几个方面。<br><br>生物仿制药法规政策&#34;急人&#34;<br><br>欧盟生物仿制药政策最早得到完善，已于2005年出台《生物仿制药指导原则》，2006～2010年陆续出台9个细分领域的指导守则，现已有7个生物仿制药上市；而美国已于两个星期前出台了新的针对生物仿制药的法规；日本、韩国、加拿大、WHO等国家和组织参照欧盟，相继出台了生物仿制药申请指导原则。目前中国生物仿制药开发主要参考FDA，EMA，ICH关于生物药物开发原则和指南，国内目前已有大量生物仿制药上市，但还没有明确的生物仿制药法规。<br><br>我国抗体类药物的市场化刚刚起步，主要表现为工艺水平不高，产业化规模较小，相关科技人才不足，缺乏核心技术，产学研脱节等。鉴于国内企业纷纷上马生物仿制药项目，急需良好的药物研发指导原则，因此中国生物仿制药法规的早日出台对规范国家生物仿制药行业发展，促进产学研投资机构的积极性至关重要。<br><br>开发生物仿制药已经是未来几年医药行业的趋势，&#34;识时务者为俊杰&#34;，学术界和工业界对生物仿制药的开发技术进行广泛深入的交流探讨对行业的良好发展具有极大的推进作用。生物仿制药的前景很美好，同时也面临着极为严峻的技术和资金挑战，谁能最终在这场&#34;没有硝烟的战争&#34;中胜出，我们拭目以待。（生物谷Bioon.com）<br><br>(责任编辑：lili.zhao)<br><br><a href=\"http://xueqiu.com/S/PRE317\"   target=\"_blank\">$中信国健(PRE317)$</a> <a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a>","source":"雪球"},{"id":23927583,"user_id":6785033954,"title":"Regeneron和赛诺菲哮喘药dupilumab有望成为改变游戏规则的药物","created_at":1369223408000,"retweet_count":1,"reply_count":1,"fav_count":1,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"2013年5月22日讯 /生物谷BIOON/ --赛诺菲（Sanofi）和Regeneron制药21日宣布，在中度至重度过敏性哮喘（allergic asthma）患者中开展的有关实验性单抗药物dupilumab的IIa期临床试验取得了积极数据，研究的详细数据已在线发表于《新英格兰医学杂志》（New England Journal of Medicine），同时也已...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23927583","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":299,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 19:50","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"2013年5月22日讯 /生物谷BIOON/ --赛诺菲（Sanofi）和Regeneron制药21日宣布，在中度至重度过敏性哮喘（allergic asthma）患者中开展的有关实验性单抗药物dupilumab的IIa期临床试验取得了积极数据，研究的详细数据已在线发表于《新英格兰医学杂志》（New England Journal of Medicine），同时也已提交至21日在费城举行的美国胸腔学会（American Thoracic Society）年度科学会议。<br><br>Dupilumab是一种新型哮喘药物，旨在攻击导致哮喘的最根本病因，在该项IIa期研究中，dupilumab消减了87%的哮喘发作。对于中度至重度过敏性哮喘患者来说，dupilumab有望成为一个改变游戏规则的药物。<br><br>该项研究的首席研究员Sally Wenzel博士称，总体来说，这些数据是近20年中在哮喘临床试验中所取得的最激动人心的数据。<br><br>该项概念验证（proof-of-concept）试验，共纳入了104例用吸入性糖皮质激素（ICS）和长效β受体激动剂（LABA）疗法不能良好控制、同时伴有血压升高或痰液中含高水平嗜酸性粒细胞的中度至重度持续性哮喘患者。该项研究以痰液高水平嗜酸性粒细胞作为一种生物标志物，痰液嗜酸性粒细胞水平的升高，预示着与过敏和哮喘相关的免疫系统细胞（Th2辅助细胞）已经被激活。<br><br>该项研究的主要目标是评估为期12周、每周皮下注射300mg dupilumab的疗效。研究中，安慰剂组有23例（44.2%）经历了哮喘发作，而dupilumab治疗组仅有3例，与安慰剂相比，dupilumab使哮喘发作发病率降低了87%（p＜0.0001），达到了研究的主要终点。此外，该项研究也达到了所有的次要终点，包括症状、肺功能的改善，以及对标准药物β激动剂需求的减少。<br><br>尽管需要开展更大型的临床试验来证实此次概念验证试验的结果，但研究人员对此非常乐观。他们还指出，dupilumab也有能力治疗特应性皮炎（atopic dermatitis，AD）或严重的湿疹，这是一种过敏性疾病，目前还没有能够很好控制的药物。<br><br>Wenzel在接受采访时称，目前哮喘的治疗一直是类似于创可贴疗法，这些疗法没有攻击到疾病的根本原因，而dupilumab可能能够解决疾病根源问题。<br><br>Dupilumab (SAR231893/REGN668)是一种全人源化单克隆抗体，直接靶向白介素4受体(IL-4R)的α亚基，由Regeneron公司利用其开创性的Veloclmmune技术开发，目前该公司正与赛诺菲合作开发dupilumab。<br><br>通过阻断IL-4Rα亚基，dupilumab能够调节Th2免疫应答中2种驱动子IL-13和IL-4的信号通路，这2种蛋白已被证明与炎症相关。<br><br>目前，有关dupilumab治疗特应性皮炎和哮喘的研究正在进行中。（生物谷bioon.com）","source":"雪球"},{"id":23927527,"user_id":6785033954,"title":"上海生物医药经济总量超两千亿","created_at":1369222897000,"retweet_count":1,"reply_count":0,"fav_count":2,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"<a href=\"http://www.stdaily.com\" title=\"http://www.stdaily.com\"  target=\"_blank\">http://www.stdaily.com</a> 2013年05月22日 来源： 科技日报 作者： 王春 科技日报讯 （记者王春）在5月14日举行的上海市政府新闻发布会上，上海市科委主任寿子琪介绍了上海近3年生物医药产业的发展情况。2012年，上海市生物医药行业经济总量达到2084.75亿元，比2008年翻了一番。4年来，上海全社会生...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23927527","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":362,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 19:41","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<a href=\"http://www.stdaily.com\" title=\"http://www.stdaily.com\"  target=\"_blank\">http://www.stdaily.com</a> 2013年05月22日 来源： 科技日报 作者： 王春<br><br>&nbsp; &nbsp;&nbsp;科技日报讯 （记者王春）在5月14日举行的上海市政府新闻发布会上，上海市科委主任寿子琪介绍了上海近3年生物医药产业的发展情况。2012年，上海市生物医药行业经济总量达到2084.75亿元，比2008年翻了一番。4年来，上海全社会生物医药产业固定资产投资完成总额超160亿元，有望成为新的经济增长点。<br><br>&nbsp; &nbsp;&nbsp;据悉，2012年上海销售额过亿元的生物医药产品已超过100个。寿子琪表示，在拳头产品方面，目前微创公司的药物洗脱血管支架、凯宝药业的痰热清注射液等6个产品销售额超过10亿元；海尼药业的转化糖电解质注射液、新亚、新先锋的头孢曲松钠、和黄药业的麝香保心丸、中信国健的益赛普、康德莱的注射穿刺器械、东富龙的冻干机等11个产品销售额超过5亿元。<br><br>&nbsp; &nbsp;&nbsp;据了解，根据发展行动计划，浦东、闵行、徐汇、奉贤、金山、青浦确立了6个产业基地，在推进过程中，上海市政府给予了相应的扶持和补贴。目前，6个产业基地实现制造业产值占全市制造业总产值的80%，上海市生物医药新增投资产业项目的80%以上也集中在6个产业基地。<br><br>(科技日报)","source":"雪球"},{"id":23927449,"user_id":6785033954,"title":"贵州茅台关注度高 近期终端销售好转","created_at":1369222408000,"retweet_count":3,"reply_count":2,"fav_count":1,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"今日投资财经资讯有限公司量化研究显示，近一周“分析师关注度最高”的前20只股票中，信息服务类股票4只；商业贸易、机械设备类股票各3只；家用电器、化工类股票各2只；其余6只个股分散于白酒、化妆品、房地产、汽车零配件、制药和建筑工程6个行业中。现就家白酒板块做简要分析。 近期白酒一改之前...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23927449","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":413,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 19:33","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"今日投资财经资讯有限公司量化研究显示，近一周“分析师关注度最高”的前20只股票中，信息服务类股票4只；商业贸易、机械设备类股票各3只；家用电器、化工类股票各2只；其余6只个股分散于白酒、化妆品、房地产、汽车零配件、制药和建筑工程6个行业中。现就家白酒板块做简要分析。<br><br>　　近期白酒一改之前颓势呈现反弹走势，尤以行业龙头公司表现突出。茅台终端销售好转、一批价企稳、估值较低等多因素叠加带动白酒板块反弹。<br><br>　　贵州茅台(199.47,4.45,2.28%)调整梢售策略，由政商务消费转向大众消费市场，近期销售好转，一批价格回升。目前茅台一批价格900元左右，较年初下降25%-30%，刺激了部分发达地区私人消费、囤酒需求的上升，也抢占了其他高端白酒的市场份额。同时公司调整销售策略，积极开发企业团购客户，短期对销售或有积极作用。国泰君安分析师胡春霞相应调高预期。<br><br>　　高端白酒价格回升。上周茅台五粮液(24.22,0.72,3.06%)老窖的淘宝网[微博]主流卖家总销量环比明显回落，但仍维持在除上周的近期最高销量水平，价格环比改善。老窖依然控量保价，销量持续低迷。预计由于价量的正循环效应，近期至少茅台销量仍将会保持比较旺盛的状态。进入6-7月销量环比回落，但相对去年同期仍保持较高景气，并在中秋节旺季出现高中低档全面的高景气。<br><br>　　国信证券分析师黄茂表示，高端白酒的销量近期仍保持在高位，但比高峰期有所回落，目前景气改善仍集中于高端尤其茅台，中高端白酒的改善信号比较微弱，随着6-7月最淡季的到来，销量会有所回落，但8-9月的旺季龙头企业或出现普遍性的企稳信号。中短期来看，仍是适度配置龙头白酒企业，等待改善信号逐渐出现。<br><br>　　中信证券(12.85,0.05,0.39%)分析师黄巍判断，目前行业PE绝对值和相对沪深300(2618.034,3.18,0.12%)估值均处在历史低位，白酒修复行情将延续，鉴于高端白酒近期维持快速走量态势，维持白酒行业“推荐”的投资评级。同时指出，白酒行业调整期，应当从产品品牌、历史文化、企业管理、产品梯度和渠道营销等多方面考虑，精选最具穿越行业调整周期的优质公司，首选贵州茅台。<br><br>　　近日，人民日报发表文章《别把应该当“不该”》，针对目前限制“三公”消费过程中出现的一些矫枉过正现象做了点评。文章指出，“正常会议正常开，抓紧时间、简化程序，就应该；正常接待正常做，不超标准、不乱花钱，就可以。如果为转作风而转作风，影响到工作开展，反而是舍本逐末、得不偿失了。这不仅有违转作风本义，而且会让这一活动失去‘可持续开展’能力。”这一信息符合行业分析师前期报告中关于限制“三公”消费政策短期矫枉过正，未来将回归理性的判断。","source":"雪球"},{"id":23927391,"user_id":6785033954,"title":"中国酒商的财富新机遇——五粮液冰珀43","created_at":1369222185000,"retweet_count":4,"reply_count":6,"fav_count":3,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"导读：在这个中国夜场不乏繁荣的时代，入驻中国夜场的夜场酒品牌虽多，却找不到一瓶属于中国酿造的酒！洋酒的垄断，假酒的泛滥而行，使得酒业产业规范和管理遭到破坏，严重损害了经销商和消费者的切身利益。 在这个中国夜场不乏繁荣的时代，入驻中国夜场的夜场酒品牌虽多，却找不到一瓶属于中国酿...","type":"3","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23927391","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":357,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 19:29","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"导读：在这个中国夜场不乏繁荣的时代，入驻中国夜场的夜场酒品牌虽多，却找不到一瓶属于中国酿造的酒！洋酒的垄断，假酒的泛滥而行，使得酒业产业规范和管理遭到破坏，严重损害了经销商和消费者的切身利益。<br><br>在这个中国夜场不乏繁荣的时代，入驻中国夜场的夜场酒品牌虽多，却找不到一瓶属于中国酿造的酒！洋酒的垄断，假酒的泛滥而行，使得酒业产业规范和管理遭到破坏，严重损害了经销商和消费者的切身利益。<br><br>　　<br>在这个外国品牌肆意瓜分中国夜场的局势下，中国也在自我苏醒。经过了10年酝酿，五粮液集团从前期的战略筹备转入实质性的营销竞争上来，隆重推出了一款专为夜场而生的精品——五粮液冰珀43。这不仅标志着国酒争夺夜场之战的开始，更标志着“中国国酒不能流行于夜场”的荒诞被粉碎。<br>　　<br>夜场消费跟中国传统酒水消费特点明显不同，特别是在洋酒盛行的消费氛围之下，想形成独立的地方割据市场是非常困难的。所以，在这场战役中，冰珀43在抢占国内夜场的同时，也在树立国际化的品牌，将这场持久而全面的战役坚持到底！<br>　　<br>在这样的背景下，国家也给予了五粮液冰珀43良好的发展前景：高度酒向低度酒转变；烈性酒向营养型酒转变；勾兑浸泡类酒向发酵类酒转变；粮食类酒向果露类酒转变。加之，五粮液冰珀43出鞘就拥有的七重保障，使得冰珀43代表一种新势力、新姿势、新形象、新概念，新思维，势如破竹般地打开了新市场，为中国酒商创造了新的财富机遇。<br><br>所谓“众人拾柴火焰高”，在这一场长久之战中，五粮液冰珀43并不满足与此，还以其绝佳的加盟条件，诚邀认同其经营理念、拥有良好的商业信誉和一定的经济实力、有着完善的终端网络或较强的终端开发能力、专项资金和人员投入并愿意投入人力、物力、财力进行长期市场运作、具有独立的法人资格或具备经销酒水的资格、有合理的库存管理制度和完善的配送体系、有先进的服务理念和完备的服务支持系统、具有旺盛的事业信心、遵守本公司市场管理制度和市场规划的合作伙伴，用共同的努力，成功实现1+1大于2。<br>　　<br>而加盟者也将在此过程获得五粮液公司的“全程护航”：获得区域独家经销权支持、宣传推广、促销、培训、市场管理以及其他市场支持。打破夜场“黑势力”，让中国酒商们真正体验到国酒带来的巨大财富与惊喜。<br>　　<br>品牌与品质双驱动，五粮液冰珀43犹如闪耀在夜空的精灵，打破格局，为中国酒业开辟出一片新天地！","source":"雪球"},{"id":23927347,"user_id":6785033954,"title":"","created_at":1369221745000,"retweet_count":0,"reply_count":1,"fav_count":2,"truncated":false,"commentId":21791003,"retweet_status_id":23881062,"symbol_id":null,"description":"叶茂中广告团队一经典广告语“我敬你一万年”倡导中国第一款敬文化酒“五粮液冰珀43”的诞生，刚刚登陆重庆，就以不同寻常的稀有血统赢得了人们的关注。 原料稀有1999年五粮液集团耗资2亿窖藏万吨果酒原浆，冰珀43起步既同步五粮液百年品质标准。 工艺稀有30%五粮液保密工艺结合70%白兰地工艺，被...","type":null,"source_link":null,"edited_at":null,"pic":null,"user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":{"id":23881062,"user_id":6785033954,"title":"冰珀43——中国首席夜场酒品牌","created_at":1368794422000,"retweet_count":47,"reply_count":73,"fav_count":18,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"到现在没人关心五粮液花重资精心打造的冰珀43，这真是一款无足轻重的品牌吗，恰恰相反，我认为冰珀43是五粮液开辟夜场酒市场和国际市场的利剑，在五粮液整个战略布局中起着相当关键的作用。中国白酒一直打不开国际市场很大的原因就是，不时尚，中国白酒文化无法被外国人所接受。缺乏时尚元素的中国...","type":"3","source_link":null,"edited_at":1369411673000,"pic":"http://xqimg.imedao.com/13eb280637d303fe6781bf91.jpg!thumb.jpg,http://xqimg.imedao.com/13ed74b5d144e3fea512b3cf.jpg!thumb.jpg,http://xqimg.imedao.com/13eb274ea39283fb7a78788b.jpg!thumb.jpg,http://xqimg.imedao.com/13ed74bc79e443fdeffef0ff.jpg!thumb.jpg","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23881062","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":0,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-17 20:40","expend":true,"canEdit":true,"firstImg":"http://xqimg.imedao.com/13eb280637d303fe6781bf91.jpg!thumb.jpg","topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"到现在没人关心五粮液花重资精心打造的冰珀43，这真是一款无足轻重的品牌吗，恰恰相反，我认为冰珀43是五粮液开辟夜场酒市场和国际市场的利剑，在五粮液整个战略布局中起着相当关键的作用。中国白酒一直打不开国际市场很大的原因就是，不时尚，中国白酒文化无法被外国人所接受。缺乏时尚元素的中国白酒做出的夜场酒居然不输任何一款世界顶级美酒，这是让我想不到的。<br><br>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;五粮液冰珀43是五粮液集团唐桥董事长亲自推荐，五粮液集团董事陈林和果酒大师林红通过12年不懈努力，亲自研发的酒，无论是它的出生还是品质都是补充高端缺口最佳第一选择。对于冰珀43的发展，五粮液集团唐桥董事长坚定地表示：“冰珀43是五粮液集团针对夜场打造的唯一高端战略品牌，我们要打造最优质的美酒，诠释中国人最深的敬意！再创一个百亿品牌神话！”<br><br>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;仅采用冰酒低温发酵技术、白兰地蒸馏技术还不够，口感的关键在于配方，再好的果酒原浆，如果配方不够好，都会影响酒的风味。为创造出独傲群雄的稀有口感，冰珀研发团队尝试了上百种配方，历经上千次试酿，才使得冰珀43入口非常柔和，花果芬芳一下子就融化在嘴里，如行春郊，如梦如醉，醉的舒服，醉的恰如其分，次日还不会一身酒气。法国品酒大师团盲品后，不能相信口感第一的酒，居然来自中国，连声赞叹：“东方白兰地，神奇的黄金液体！”<br><br>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;中国夜场酒一年至少有3000亿的市场份额，一直以来都被洋品牌所垄断。洋酒渠道混乱，整个市场对洋酒的消费信心有疑虑。经过12年的酝酿，冰珀43上市短短数月，得到了所有夜店老板的支持，90%以上的老板表示要亲自来抓，超过50%的老板有做分销商的意愿，在地级市场单店就能销售200瓶—500瓶，而洋酒十几个品牌共卖不到两百瓶。全国市场的红火销售是指日可待！<br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13eb280637d303fe6781bf91.jpg!custom.jpg\" /><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ed74b5d144e3fea512b3cf.jpg!custom.jpg\" /><br><br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13eb274ea39283fb7a78788b.jpg!custom.jpg\" /><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ed74bc79e443fdeffef0ff.jpg!custom.jpg\" /><br><br><br><a href=\"http://www.wlybp43.com\" title=\"http://www.wlybp43.com\"  target=\"_blank\">http://www.wlybp43.com</a><br>五粮液冰珀43—全国运营中心<br><br><a href=\"http://www.56.com/u92/v_ODQwNDExMzc.html\" title=\"http://www.56.com/u92/v_ODQwNDExMzc.html\"  target=\"_blank\">http://www.56.com/u92/v_ODQwNDExMzc.html</a><br>冰珀43——东方白兰地","source":"雪球"},"target":"/6785033954/23927347","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":367,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 19:22","expend":true,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"叶茂中广告团队一经典广告语“我敬你一万年”倡导中国第一款敬文化酒“五粮液冰珀43”的诞生，刚刚登陆重庆，就以不同寻常的稀有血统赢得了人们的关注。<br><br>原料稀有1999年五粮液集团耗资2亿窖藏万吨果酒原浆，冰珀43起步既同步五粮液百年品质标准。<br><br>工艺稀有30%五粮液保密工艺结合70%白兰地工艺，被法国品酒大师誉为“东方白兰地”。<br><br>口感稀有五粮液集团白酒大师、果酒大师强强联合，将“五种粮食酿造”升级为“五种果实酿造”，使得冰珀43口感绝佳，酒气散得快，更符合现代人的健康需求。<br><br>产量稀有为确保真品质，维护消费者利益，五粮液集团甄选高信誉度商家，“限店、限量”销售冰珀43。","source":"雪球"},{"id":23927327,"user_id":6785033954,"title":"","created_at":1369221610000,"retweet_count":1,"reply_count":1,"fav_count":2,"truncated":false,"commentId":21790997,"retweet_status_id":23881062,"symbol_id":null,"description":"【精选酒品】 五粮液冰珀43 类型：馥郁型果酒 产地：四川宜宾 酿造原料：精选优质青梅、石榴、香橙、葡萄、杏仁、大米、茶等多种天然水果与粮食为原料，通过发酵与蒸馏等生产工艺酿制而成。 酒精度：43% 陈酿时间：10年窖藏陈酿。 五粮液冰珀43是五粮液专门针对夜场打造的中国首款高端夜场酒民族品...","type":null,"source_link":null,"edited_at":null,"pic":null,"user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":{"id":23881062,"user_id":6785033954,"title":"冰珀43——中国首席夜场酒品牌","created_at":1368794422000,"retweet_count":47,"reply_count":73,"fav_count":18,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"到现在没人关心五粮液花重资精心打造的冰珀43，这真是一款无足轻重的品牌吗，恰恰相反，我认为冰珀43是五粮液开辟夜场酒市场和国际市场的利剑，在五粮液整个战略布局中起着相当关键的作用。中国白酒一直打不开国际市场很大的原因就是，不时尚，中国白酒文化无法被外国人所接受。缺乏时尚元素的中国...","type":"3","source_link":null,"edited_at":1369411673000,"pic":"http://xqimg.imedao.com/13eb280637d303fe6781bf91.jpg!thumb.jpg,http://xqimg.imedao.com/13ed74b5d144e3fea512b3cf.jpg!thumb.jpg,http://xqimg.imedao.com/13eb274ea39283fb7a78788b.jpg!thumb.jpg,http://xqimg.imedao.com/13ed74bc79e443fdeffef0ff.jpg!thumb.jpg","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23881062","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":0,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-17 20:40","expend":true,"canEdit":true,"firstImg":"http://xqimg.imedao.com/13eb280637d303fe6781bf91.jpg!thumb.jpg","topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"到现在没人关心五粮液花重资精心打造的冰珀43，这真是一款无足轻重的品牌吗，恰恰相反，我认为冰珀43是五粮液开辟夜场酒市场和国际市场的利剑，在五粮液整个战略布局中起着相当关键的作用。中国白酒一直打不开国际市场很大的原因就是，不时尚，中国白酒文化无法被外国人所接受。缺乏时尚元素的中国白酒做出的夜场酒居然不输任何一款世界顶级美酒，这是让我想不到的。<br><br>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;五粮液冰珀43是五粮液集团唐桥董事长亲自推荐，五粮液集团董事陈林和果酒大师林红通过12年不懈努力，亲自研发的酒，无论是它的出生还是品质都是补充高端缺口最佳第一选择。对于冰珀43的发展，五粮液集团唐桥董事长坚定地表示：“冰珀43是五粮液集团针对夜场打造的唯一高端战略品牌，我们要打造最优质的美酒，诠释中国人最深的敬意！再创一个百亿品牌神话！”<br><br>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;仅采用冰酒低温发酵技术、白兰地蒸馏技术还不够，口感的关键在于配方，再好的果酒原浆，如果配方不够好，都会影响酒的风味。为创造出独傲群雄的稀有口感，冰珀研发团队尝试了上百种配方，历经上千次试酿，才使得冰珀43入口非常柔和，花果芬芳一下子就融化在嘴里，如行春郊，如梦如醉，醉的舒服，醉的恰如其分，次日还不会一身酒气。法国品酒大师团盲品后，不能相信口感第一的酒，居然来自中国，连声赞叹：“东方白兰地，神奇的黄金液体！”<br><br>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;中国夜场酒一年至少有3000亿的市场份额，一直以来都被洋品牌所垄断。洋酒渠道混乱，整个市场对洋酒的消费信心有疑虑。经过12年的酝酿，冰珀43上市短短数月，得到了所有夜店老板的支持，90%以上的老板表示要亲自来抓，超过50%的老板有做分销商的意愿，在地级市场单店就能销售200瓶—500瓶，而洋酒十几个品牌共卖不到两百瓶。全国市场的红火销售是指日可待！<br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13eb280637d303fe6781bf91.jpg!custom.jpg\" /><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ed74b5d144e3fea512b3cf.jpg!custom.jpg\" /><br><br><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13eb274ea39283fb7a78788b.jpg!custom.jpg\" /><br><img class=\"ke_img\" src=\"http://xqimg.imedao.com/13ed74bc79e443fdeffef0ff.jpg!custom.jpg\" /><br><br><br><a href=\"http://www.wlybp43.com\" title=\"http://www.wlybp43.com\"  target=\"_blank\">http://www.wlybp43.com</a><br>五粮液冰珀43—全国运营中心<br><br><a href=\"http://www.56.com/u92/v_ODQwNDExMzc.html\" title=\"http://www.56.com/u92/v_ODQwNDExMzc.html\"  target=\"_blank\">http://www.56.com/u92/v_ODQwNDExMzc.html</a><br>冰珀43——东方白兰地","source":"雪球"},"target":"/6785033954/23927327","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":321,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 19:20","expend":true,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"【精选酒品】<br><br>五粮液冰珀43<br><br>类型：馥郁型果酒<br><br>产地：四川宜宾<br><br>酿造原料：精选优质青梅、石榴、香橙、葡萄、杏仁、大米、茶等多种天然水果与粮食为原料，通过发酵与蒸馏等生产工艺酿制而成。<br><br>酒精度：43%<br><br>陈酿时间：10年窖藏陈酿。<br><br>五粮液冰珀43是五粮液专门针对夜场打造的中国首款高端夜场酒民族品牌，没有之一。五粮液冰珀酒有“破冰解码”独特饮用特征，因为冰块能打破冰珀酒看似宁静的和谐“外表”，能有效激活冰珀酒原本丰富的诸多“潜能”，这里的“冰”实际上就是冰珀酒的一个酒体解码器，一把通向奇特酒世界的钥匙。琥珀的漫长沉积历程寓意着冰珀酒的长时间陈酿与醇化过程，都是人间精髓的象征，都是时间凝聚的产物。<br><br>在中国自己这么大的市场内，长期以来居然没有一款中国自主的畅销酒品。冰珀43是五粮液股份有限公司荣耀出品的世界级酒品，强势入驻中国夜场，填补了中国自主夜场酒市场真空，开启中国夜场酒的历史新纪元。<br><br>品鉴：一般的果露类酒都只有10多度，冰珀43无论是在工艺上还是在度数、口感等方面都是一次全新的突破，它酸、甜、苦、辣、鲜五味俱全，具有多种天然复合香气和口味。加冰块是冰珀43比较经典的喝法，冰火交融的快乐，无法忘却的情怀。","source":"雪球"},{"id":23923296,"user_id":6785033954,"title":"","created_at":1369201221000,"retweet_count":0,"reply_count":8,"fav_count":1,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"<a href=\"http://xueqiu.com/S/SZ000858\"   target=\"_blank\">$五粮液(SZ000858)$</a> 五粮液获得了新生，曾经那个半死不活的五粮液永远不会再出现了。","type":"0","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23923296","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":323,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 13:40","expend":false,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<a href=\"http://xueqiu.com/S/SZ000858\"   target=\"_blank\">$五粮液(SZ000858)$</a> 五粮液获得了新生，曾经那个半死不活的五粮液永远不会再出现了。","source":"雪球"},{"id":23923205,"user_id":6785033954,"title":"","created_at":1369200620000,"retweet_count":1,"reply_count":3,"fav_count":1,"truncated":false,"commentId":21788494,"retweet_status_id":23915698,"symbol_id":null,"description":"浴火重生，不要再用老眼光看待五粮液，投资五粮液的最佳时机来临。","type":null,"source_link":null,"edited_at":null,"pic":null,"user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":{"id":23915698,"user_id":6785033954,"title":"","created_at":1369142463000,"retweet_count":11,"reply_count":25,"fav_count":1,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"<a href=\"http://xueqiu.com/S/SZ000858\"   target=\"_blank\">$五粮液(SZ000858)$</a> 这次白酒危机让五粮液浴火重生，走出底部后五粮液将踏上长达数年的慢牛之路。","type":"0","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23915698","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":0,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-21 21:21","expend":false,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<a href=\"http://xueqiu.com/S/SZ000858\"   target=\"_blank\">$五粮液(SZ000858)$</a> 这次白酒危机让五粮液浴火重生，走出底部后五粮液将踏上长达数年的慢牛之路。","source":"雪球"},"target":"/6785033954/23923205","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":310,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-22 13:30","expend":false,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"浴火重生，不要再用老眼光看待五粮液，投资五粮液的最佳时机来临。","source":"雪球"},{"id":23917281,"user_id":6785033954,"title":"","created_at":1369149049000,"retweet_count":2,"reply_count":8,"fav_count":2,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"<a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a> 中信国健去年大规模的招兵买马，销售网络布局全国，投入相当大，今年的利好不断，益赛普进军印度墨西哥市场，连续进入各省市医保药物招标，治疗乳腺癌的赛普汀今年上市。。。今年中信国健的业绩会小爆发一下，明年将出现大爆发，后年开始持续进入高增长，千亿市值15年实现是...","type":"0","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23917281","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":342,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-21 23:10","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a> 中信国健去年大规模的招兵买马，销售网络布局全国，投入相当大，今年的利好不断，益赛普进军印度墨西哥市场，连续进入各省市医保药物招标，治疗乳腺癌的赛普汀今年上市。。。今年中信国健的业绩会小爆发一下，明年将出现大爆发，后年开始持续进入高增长，千亿市值15年实现是必然。","source":"雪球"},{"id":23917123,"user_id":6785033954,"title":"","created_at":1369148409000,"retweet_count":1,"reply_count":4,"fav_count":0,"truncated":false,"commentId":21784682,"retweet_status_id":23910282,"symbol_id":null,"description":"回复<a href=\"http://xueqiu.com/n/微笑如风\"  target=\"_blank\">@微笑如风</a>: 我是想说值200亿，怕没人信，少说了一半，你去看看2012年全球药物销量前十名单抗占了几位。里面所有单抗药中信国健都有且即将上市，一个单抗药就可卖到上百亿美金，你说中信国健值多少钱，兰生股份值多少钱。//<a href=\"http://xueqiu.com/n/微笑如风\"  target=\"_blank\">@微笑如风</a>:回复<a href=\"http://xueqiu.com/n/zangyn\"  target=\"_blank\">@zangyn</a>:15%股份值得100亿？这个似乎有点多了，这样就等...","type":null,"source_link":null,"edited_at":null,"pic":null,"user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":{"id":23910282,"user_id":6785033954,"title":"中信国健——中国医药皇冠上最璀璨的明珠","created_at":1369114683000,"retweet_count":12,"reply_count":19,"fav_count":6,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"<a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a> 美国治疗类风湿的修美乐、类克、恩利三款单抗药物2012年销售额超过250亿美元，随着中信国健销售团队的全国布局，益赛普进入更多省市医保，在海外市场上连续的重大突破，未来销售十亿美元并不是奢望。今年即将上市的赛普汀更是值得期待的重磅产品，治疗非霍奇金淋巴瘤的健妥昔...","type":"3","source_link":null,"edited_at":1369116100000,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23910282","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":0,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-21 13:38","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a> 美国治疗类风湿的修美乐、类克、恩利三款单抗药物2012年销售额超过250亿美元，随着中信国健销售团队的全国布局，益赛普进入更多省市医保，在海外市场上连续的重大突破，未来销售十亿美元并不是奢望。今年即将上市的赛普汀更是值得期待的重磅产品，治疗非霍奇金淋巴瘤的健妥昔，治疗转移性结直肠癌的重组抗EGFR人鼠嵌合单克隆抗体也将在14年—15年上市，更是有白血病、哮喘、肝癌等三十多个单抗新药处于临床及临床报批状态。未来的中信国健无可限量，中国医药皇冠上最璀璨的明珠非中信国健莫属。","source":"雪球"},"target":"/6785033954/23917123","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":311,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-21 23:00","expend":true,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"回复<a href=\"http://xueqiu.com/n/微笑如风\"  target=\"_blank\">@微笑如风</a>: 我是想说值200亿，怕没人信，少说了一半，你去看看2012年全球药物销量前十名单抗占了几位。里面所有单抗药中信国健都有且即将上市，一个单抗药就可卖到上百亿美金，你说中信国健值多少钱，兰生股份值多少钱。//<a href=\"http://xueqiu.com/n/微笑如风\"  target=\"_blank\">@微笑如风</a>:回复<a href=\"http://xueqiu.com/n/zangyn\"  target=\"_blank\">@zangyn</a>:15%股份值得100亿？这个似乎有点多了，这样就等于说国健一个亿的净利润对应620亿的市值，市净率就是市梦率了","source":"雪球"},{"id":23916645,"user_id":6785033954,"title":"","created_at":1369146645000,"retweet_count":3,"reply_count":10,"fav_count":2,"truncated":false,"commentId":21784358,"retweet_status_id":23910282,"symbol_id":null,"description":"回复<a href=\"http://xueqiu.com/n/威廉力牛\"  target=\"_blank\">@威廉力牛</a>: 要是所占比例多的话能是现在的股价吗，这15%的股份就值一百个亿。目前兰生市值才多少，再加上1.9亿海通股权，价值30亿的兰生大厦（兰生占48%的股份），你算算兰生值多少钱 。//<a href=\"http://xueqiu.com/n/威廉力牛\"  target=\"_blank\">@威廉力牛</a>:回复<a href=\"http://xueqiu.com/n/zangyn\"  target=\"_blank\">@zangyn</a>:可是，兰生所占的股份并不多啊。","type":null,"source_link":null,"edited_at":null,"pic":null,"user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":{"id":23910282,"user_id":6785033954,"title":"中信国健——中国医药皇冠上最璀璨的明珠","created_at":1369114683000,"retweet_count":12,"reply_count":19,"fav_count":6,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"<a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a> 美国治疗类风湿的修美乐、类克、恩利三款单抗药物2012年销售额超过250亿美元，随着中信国健销售团队的全国布局，益赛普进入更多省市医保，在海外市场上连续的重大突破，未来销售十亿美元并不是奢望。今年即将上市的赛普汀更是值得期待的重磅产品，治疗非霍奇金淋巴瘤的健妥昔...","type":"3","source_link":null,"edited_at":1369116100000,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23910282","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":0,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-21 13:38","expend":true,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<a href=\"http://xueqiu.com/S/SH600826\"   target=\"_blank\">$兰生股份(SH600826)$</a> 美国治疗类风湿的修美乐、类克、恩利三款单抗药物2012年销售额超过250亿美元，随着中信国健销售团队的全国布局，益赛普进入更多省市医保，在海外市场上连续的重大突破，未来销售十亿美元并不是奢望。今年即将上市的赛普汀更是值得期待的重磅产品，治疗非霍奇金淋巴瘤的健妥昔，治疗转移性结直肠癌的重组抗EGFR人鼠嵌合单克隆抗体也将在14年—15年上市，更是有白血病、哮喘、肝癌等三十多个单抗新药处于临床及临床报批状态。未来的中信国健无可限量，中国医药皇冠上最璀璨的明珠非中信国健莫属。","source":"雪球"},"target":"/6785033954/23916645","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":372,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-21 22:30","expend":false,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"回复<a href=\"http://xueqiu.com/n/威廉力牛\"  target=\"_blank\">@威廉力牛</a>: 要是所占比例多的话能是现在的股价吗，这15%的股份就值一百个亿。目前兰生市值才多少，再加上1.9亿海通股权，价值30亿的兰生大厦（兰生占48%的股份），你算算兰生值多少钱 。//<a href=\"http://xueqiu.com/n/威廉力牛\"  target=\"_blank\">@威廉力牛</a>:回复<a href=\"http://xueqiu.com/n/zangyn\"  target=\"_blank\">@zangyn</a>:可是，兰生所占的股份并不多啊。","source":"雪球"},{"id":23915915,"user_id":6785033954,"title":"","created_at":1369143444000,"retweet_count":3,"reply_count":14,"fav_count":3,"truncated":false,"commentId":21783742,"retweet_status_id":23915698,"symbol_id":null,"description":"回复<a href=\"http://xueqiu.com/n/般若波罗蜜\"  target=\"_blank\">@般若波罗蜜</a>: 一年涨幅达到20%就可以称为慢牛，以今天的收盘价对应13年年底股价28.20元，14年33.84元，15年40.60元，16年48.73元，17年58.47元。预计13年到17年业绩3元，3.4元，4元，5.2元，6元。动态PE始终保持在十倍以下。这个目标在熊市中也可以轻松实现。//<a href=\"http://xueqiu.com/n/般若波罗蜜\"  target=\"_blank\">@般若波罗蜜</a>:回复<a href=\"http://xueqiu.com/n/zangyn\"  target=\"_blank\">@zangyn</a>:是不是...","type":null,"source_link":null,"edited_at":null,"pic":null,"user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":{"id":23915698,"user_id":6785033954,"title":"","created_at":1369142463000,"retweet_count":11,"reply_count":25,"fav_count":1,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"<a href=\"http://xueqiu.com/S/SZ000858\"   target=\"_blank\">$五粮液(SZ000858)$</a> 这次白酒危机让五粮液浴火重生，走出底部后五粮液将踏上长达数年的慢牛之路。","type":"0","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23915698","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":0,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-21 21:21","expend":false,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<a href=\"http://xueqiu.com/S/SZ000858\"   target=\"_blank\">$五粮液(SZ000858)$</a> 这次白酒危机让五粮液浴火重生，走出底部后五粮液将踏上长达数年的慢牛之路。","source":"雪球"},"target":"/6785033954/23915915","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":310,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-21 21:37","expend":true,"canEdit":false,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"回复<a href=\"http://xueqiu.com/n/般若波罗蜜\"  target=\"_blank\">@般若波罗蜜</a>: 一年涨幅达到20%就可以称为慢牛，以今天的收盘价对应13年年底股价28.20元，14年33.84元，15年40.60元，16年48.73元，17年58.47元。预计13年到17年业绩3元，3.4元，4元，5.2元，6元。动态PE始终保持在十倍以下。这个目标在熊市中也可以轻松实现。//<a href=\"http://xueqiu.com/n/般若波罗蜜\"  target=\"_blank\">@般若波罗蜜</a>:回复<a href=\"http://xueqiu.com/n/zangyn\"  target=\"_blank\">@zangyn</a>:是不是有点乐观了","source":"雪球"},{"id":23915698,"user_id":6785033954,"title":"","created_at":1369142463000,"retweet_count":11,"reply_count":25,"fav_count":1,"truncated":false,"commentId":0,"retweet_status_id":0,"symbol_id":null,"description":"<a href=\"http://xueqiu.com/S/SZ000858\"   target=\"_blank\">$五粮液(SZ000858)$</a> 这次白酒危机让五粮液浴火重生，走出底部后五粮液将踏上长达数年的慢牛之路。","type":"0","source_link":null,"edited_at":null,"pic":"","user":{"subscribeable":false,"status":1,"common_count":0,"remark":null,"name":null,"location":null,"id":6785033954,"type":"1","url":null,"description":"如果不上雪球，你就输在了投资的起跑线上。","domain":null,"stats":null,"blocking":false,"screen_name":"zangyn","verified":false,"verified_type":0,"st_color":"1","allow_all_stock":false,"following":false,"donate_count":47,"verified_description":null,"profile":"/6785033954","status_count":7506,"last_status_id":39401690,"follow_me":false,"friends_count":647,"city":"澳大利亚","gender":"m","followers_count":200893,"province":"海外","recommend":null,"blog_description":null,"step":"three","intro":null,"stock_status_count":null,"stocks_count":null,"group_ids":null,"name_pinyin":null,"screenname_pinyin":null,"photo_domain":"http://xavatar.imedao.com/","profile_image_url":"community/201210/1352439404964-20121221.png,community/201210/1352439404964-20121221.png!180x180.png,community/201210/1352439404964-20121221.png!50x50.png,community/201210/1352439404964-20121221.png!30x30.png"},"retweeted_status":null,"target":"/6785033954/23915698","fragment":null,"blocked":false,"blocking":false,"topic_pic":null,"topic_symbol":null,"topic_title":null,"topic_desc":null,"donate_count":0,"donate_snowcoin":0,"view_count":337,"mark":0,"favorited":false,"favorited_created_at":null,"timeBefore":"2013-05-21 21:21","expend":false,"canEdit":true,"firstImg":null,"topic_pic_thumbnail_small":null,"topic_pic_thumbnail":null,"topic_pic_headOrPad":null,"text":"<a href=\"http://xueqiu.com/S/SZ000858\"   target=\"_blank\">$五粮液(SZ000858)$</a> 这次白酒危机让五粮液浴火重生，走出底部后五粮液将踏上长达数年的慢牛之路。","source":"雪球"}],"page":332};
  SNB.data.statusType = "";
  SNB.data.isSelf = false;
  SNB.data.who = '他';
  SNB.data.route = '';
  seajs.use(['SNB.status.js', 'SNB.newProfile.js']);
})($);</script></div><script>seajs.use(['widget/donate_tooltip'], function () {
  $('body')
    .on('click', function (e) {
      var $this =  $(e.target);
      
      if (!$this.parents('.set-sub-menu').length) {
        $('.set-sub-menu').hide();
      }
    })
    .on('mouseenter', '.status-list li', function () {
      var $this = $(this);
      
      if ($this.find('.btn-sub-menu').length) {
        $this.find('.btn-sub-menu').addClass('hover');
      }
    })
    .on('mouseleave', '.status-list li', function () {
      var $this = $(this);
      
      if ($this.find('.btn-sub-menu').length) {
        $this.find('.btn-sub-menu').removeClass('hover');
      }
    });
});

</script></div></div></div><div id="footer"><div class="risk">提示：雪球里任何用户或者嘉宾的发言，都有其特定立场，投资决策需要建立在独立思考之上。</div><div class="copyright"><a href="/about/faq" target="_blank">常见问题</a><a href="/about/contact-us" target="_blank">联系方式</a><a href="/about/jobs" target="_blank">加入我们</a><a href="/about/company" target="_blank">关于雪球</a><a>© 2015 XUEQIU.COM</a><a href="http://www.miibeian.gov.cn/" target="_blank">京ICP证100666号</a><span>京公网安备 11010502026957</span></div></div><script>var _hmt = _hmt || [];
(function () {
  var hm = document.createElement("script");
  hm.src = "https://hm.baidu.com/hm.js?1db88642e346389874251b5a1eded6e3";
  var s = document.getElementsByTagName("script")[0];
  s.parentNode.insertBefore(hm, s);
})();</script><script>var _gaq = _gaq || [];
_gaq.push(['_setAccount', 'UA-16079156-4']);
_gaq.push(['_setDomainName', 'none']);
_gaq.push(['_trackPageview']);

(function () {
  var ga = document.createElement('script');
  ga.type = 'text/javascript';
  ga.async = true;
  ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
  var s = document.getElementsByTagName('script')[0];
  s.parentNode.insertBefore(ga, s);
})();

window.onerror = function (message, file, line) {
  var sFormattedMessage = '[' + file + ' (' + line + ')]' + message;
  _gaq.push(['_trackEvent', 'Exceptions', 'Application', sFormattedMessage, null, true]);
}</script><script>jQuery(function ($) {
  $('.cube-invite').on('click', function () {
    var href = $.trim($(this).attr('href'));
    if (window._hmt) {
      _hmt.push(['_trackEvent', 'cube-invite', 'click', href]);
    }
  });
});</script></body></html>